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ABSTRACT 
 
 
TITLE OF THE ABSTRACT :  ‘An Observational study on the follow up of patients who     
                                                                  had inserton of Mirena’ 
 
 DEPARTMENT     :Department of Obstetrics and Gynaecology  
 
NAME OF THE CANDIDATE : Latha Lakshmi.K                                     
 
DEGREE AND SUBJECT  : M.S Branch II (Obstetrics and Gynaecology) 
 
NAME OF THE GUIDE  : Dr. Alice George, Professor, Department of O & G, UnitI  
 
OBJECTIVES:     
                              
 To follow up the patients, who had insertion of Mirena (Levonorgesterel intrauterine System) 
from 2007 and 2011, and to determine the effectiveness in decreasing the menstrual blood loss 
and pain after one year of insertion of Mirena ; To assess the quality of life at the end of one year 
after insertion and  satisfaction among the patients. 
 
 
METHODS:  
 
The qualitative improvement in menorrhagia was assessed using the Uterine Fibroid 
Symptom and Health related Quality of life questionnaire (UFS-QoL); The general quality of 
life at the end of one year was followed up by the SF 36 questionnaire;  The improvement in 
pain was assessed by the Visual analogue scale; The level of satisfaction was evaluated using the 
CGI- (global improvement item). Survival analysis was also done and the reason for removal 
compared by the Tarone-Ware method. 
Statistical analysis was done by a paired t test for continuous variables and the significance 
calculated. 
  
 
 
RESULTS: 
 
   
The total number of insertions from 2007 to 2011 were 353, out of which 177 patient could only 
be followed up. The rate of voluntary removal of Mirena was 10.7% and the expulsion rate was 
20%. 68.9% of patients showed symptomatic improvement; the symptom severity and the health 
related quality of life before and one year after  insertion of Mirena, improved and was 
statistically significant (p <0.01). Similarly the SF 36 showed high scores showing the better 
quality of life one year after insertion of Mirena. 
There was statistically significant reduction in pain one year after insertion of Mirena (p <0.01). 
83.5% of patients were satisfied with Mirena; However the quantitative analysis of haemoglobin, 
before and one year after insertion of mirena, though showed some improvement, was not 
statistically significant. 
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INTRODUCTION 
 
Abnormal uterine bleeding (AUB) is one of the most common reasons why 
women of the reproductive age group seek medical advice. Dysfunctional uterine 
bleeding, in the absence of a medical illness or pelvic pathology is responsible for almost 
half the cases of abnormal bleeding. 
In the first place any organic cause should be ruled out and pregnancy should be 
excluded. Structural abnormalities such as leiomyoma, polyp or endometrial hyperplasia, 
can present as heavy menstrual bleeding. Adenomyosis and endometriosis predominantly 
present with dysmenorrhea, but can also present with menorrhagia. 
There are various treatment modalities for abnormal uterine bleeding which 
includes the medical management with NSAIDs, tranexamic acid, progesterones, oral 
contraceptives, Danazol, GnRh analogues and Levonorgestrel-releasing intrauterine 
system. 
Levonorgestrel-releasing intrauterine system(Mirena), was initially developed as a  
device for contraception , which does not suppress ovulation. It is a T shaped intrauterine 
device, which releases 20 microgms of levonorgestrel daily. It prevents endometrial 
proliferation and thereby reduces the duration and the quantity of bleeding. 
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Mirena was found to be superior to all other medical therapy and the blood loss 
reduced by almost 97% at the end of one year.  
Compared to transcervical resection of the endometrium (TCRE), and balloon 
ablation, the success rate was higher in the resection and ablation group, but however the 
rate of satisfaction and change in the quality of life were similar. 64% of patients waiting 
for hysterectomy, cancelled hysterectomy when on levonorgestrel-releasing intrauterine 
system.  Mirena was also found to be cost effective compared to hysterectomy. The 
surgical morbidity associated with hysterectomy is avoided, by using this hormone 
releasing intrauterine device. 
As amenorrhea is expected in patients on Mirena, counselling should always 
include, about the advantages, side effects, the chances of expulsion of Mirena.  The need 
for continuing some other mode of medical therapy along with Mirena, for the first few 
months should also be explained prior to insertion. 
Mirena has a high efficacy in reducing the menstrual blood loss, without 
disturbing the fertility, and hence can be offered as a first line therapy for abnormal 
uterine bleeding. On the other hand hysterectomy is associated with a 100% success rate , 
in treating heavy menstrual bleeding and high patient satisfaction upto 95%, though there 
can be greater morbidity due to surgery itself. 
Mirena can also be used in patients with adenomyosis and endometriosis, and the 
principle behind is probably the atrophy of the endometrial glands and extensive 
transformation of  the decidua , caused by the chronic exposure of the  endometrium to 
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progesterones. It is successful in the patients presenting with menorrhagia of unknown 
reason. 
As quantitative assessment is not very practical , it is possible to analyse the 
qualitative improvement in the life of patients on Mirena. So the different methods used 
to assess the  qualitative improvement includes, the fibroid related symptom 
improvement and health related quality of life improvement assessment , the SF36 
scoring for the improvement in the general health after one year of insertion, the 
improvement in the pain scale and also the level of satisfaction scale. 
The above aspects were followed up in the patients who had insertion of Mirena 
from 2007 to 2011, our hospital, in the department of obstetrics and gynaecology, 
Christian Medical College and Hospital, Vellore. 
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AIMS AND OBJECTIVES 
 
 
1. To follow up patients who had Levonorgestrel releasing intrauterine system 
(Mirena) inserted from 2007 to 2011 (5 years), in the Department of Obstetrics 
and Gynaecology, Christian Medical College and Hospital, Vellore.  
 
2. To determine the effectiveness of Levonorgestrel releasing intrauterine system 
(Mirena), in  decreasing the menstrual blood loss, at the end of one year after  
insertion. 
 
3. To determine the effectiveness of Levonorgestrel releasing intrauterine system 
(Mirena)  in those with dysmenorrhea  and dyspareunia, at the end of one year 
after insertion. 
 
4. To study the health related quality of life , at the end of one year after insertion. 
 
5. To assess the level of satisfaction among those using Levenorgestrel releasing 
intrauterine system. 
6. To do survival analysis, and assess the voluntary removal and expulsion rates. 
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REVIEW OF LITERATURE 
Abnormal uterine bleeding affects 10 – 30% of women of the reproductive age 
group and about 50% of women in the perimenopausal age group. It accounts for 15% of 
office visits and almost 25% of gynecologic operations. 
The length of one menstrual cycle is 28 days and the average duration is 4 days 
and an average blood loss of 35 ml per cycle. 
Table  1: The characteristics of the normal menstrual cycle (1) 
 Average Range Abnormal 
Cycle length 28 d 21-35 d <21 or > 35 d 
Duration 4 d 1-8 d >8 d 
Blood loss 35 ml 20 – 80ml >80 ml 
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PATTERNS OF ABNORMAL UTERINE BLEEDING 
MENORRHAGIA 
  The Royal college of Obstetricians and gynaecologists, defines menorrhagia as 
“heavy cyclical bleeding over several consecutive cycles” (2). Blood loss greater than 80 
ml per cycle, is the accepted definition as far as heavy menstrual bleeding is concerned. 
Menometrorrhagia is prolonged and irregular bleeding. 
Polymenorrhea is bleeding at < 21 - day intervals 
 
POSTCOITAL BLEEDING 
It is genital tract bleeding after intercourse. Cervical cancer, polyps, ectropion or 
genital tract infection, can clinically present as bleeding . All women with postcoital 
bleeding should be referred for colposcopy, inspite of a recent negative smear test. 
 
INTERMENSTRUAL BLEEDING 
Other than during menstruation or following intercourse if a woman has bleeding 
arising from the genital tract, then it is termed so. 
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POSTMENOPAUSAL BLEEDING 
This is defined as genital tract bleeding occurring more than 12 months after the 
last menstrual period. The term menorrhagia generally points to the uterine source of 
bleeding . 
The terms postcoital bleeding, intermentstual bleeding and postmenopausal 
bleeding describe only clinical terms used for the  presentation and not refer to a specific 
site, from where the bleeding occurs. 
POSSIBLE SOURCES OF BLEEDING TO BE CONSIDERED ARE: 
1. Whole of the Genital tract 
2. Gastrointestinal tract 
3. Urinary tract 
 
THE MECHANISMS OF MENSTRUATION -THE CURRENT CONCEPTS : 
Menstruation is the process whereby the superficial or functionalis layer of the 
endometrium lining the uterine cavity disintegrates and is removed from the uterine 
lumen towards the end of the luteal phase of a non- pregnant cycle. 
The 90
th
 percentile for blood loss during menstruation was found to be 80 ml, by 
carefully measuring total menstrual loss,  and that anaemia was increased significantly in 
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women who lost  greater than 60 ml. Loss of more than 80 ml per menstrual episode, on 
the other hand  was defined as menorrhagia.  
When the patient perception of the quantity of loss is compared to objective 
measurement, there are often significant discrepancies.  25% of women whose measured 
blood loss was  normal , considered it to be “heavy”, and 40% of those with documented  
excessive flow(i.e. > 80 ml) described their loss as “light”.(3) 
 
Table 2: Menstrual blood loss- Random population studies 
 
Hallberg et al (1966) Cole et al (1971)(4) 
Mean blood loss(ml) 
  43.4 ± 2.3 37.5±3.3 
Median loss(ml) 30.0 
27.6 
Range 10.4 – 83.9 
0.1 – 280 
Loss > 60 ml 19.0% 
20.7% 
Loss > 80 ml 11.0% 
9.5% 
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MECHANISMS OF MENSTRUATION: 
Menstruation is the culmination of the changes in both the cellular and vascular 
architecture of the endometrium which follow the withdrawal of progesterone  (and 
oestrogen) at the end of the secretory phase.  
The major cellular components that contribute to menstruation are the stromal and 
vascular components. The week prior to menstruation stromal edema accompanies 
decidualization, growth of the large blood  vessels and intense coiling of the spiral 
arterioles.  
Two to six days before bleeding begins the stromal oedema shrinks,  with 
associated increase in spiral arteriolar coiling  and vascular stasis. This is followed by a 
period of vasodilation and perivascular bleeding from the wall of a capillary or arteriole, 
and then some 24 hours later by intense vasoconstriction and tissue necrosis.  70%  
approximately is lost through the vessel wall, 5% by  diapedisis and 25% by reflux from 
veins through the areas where there were previous breaks. 
There are different hypothesis that explains menstruation. 
1. The Vasoconstrictor theory:   The Vasoconstrictor hypothesis 
     This suggest 
 (a) the existence of pressor agents which play a role in vascular stasis,  
 (b) protection against excessive blood loss 
Arachidonic acids is  derived from the phospholipids present in the cell 
membranes. Prostaglandins(PG), on the other hand are synthesized from arachidonic 
acid.  
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Prostaglandin (PG) : 
 Not stored in tissues 
 Released locally and act locally 
 Rapid metabolism, and therefore a short half life  
 Have powerful stimulating properties of the vascular and smooth muscle . 
Thromboxane A2 is a vasoconstrictor and inhibitor of platelet aggregation. 
PGI2 is a vasodilator and inhibitor of aggregation 
PGF2 alpha is a vasoconstrictor and smooth muscle stimulator. 
PGE is a vasodilator  
The role of PGs in menstruation was summarized by Baird et al (5) in 1996. PG 
occurs in the menstrual fluid  and endometrium  in high concentrations,  and oestrogens 
and progestogens  influence their synthesis. PGF2alpha caused menses and an  increase 
in the uterine contractility; COX-2 inhibitors reduces blood loss during menstruation and 
inhibits increased uterine contractility associated with dysmenorrhoea. 
The Inflammatory hypothesis 
Inflammation is characterized by: 
1. Tissue oedema 
2. Inflammatory cell recruitment 
3. Pro-inflammatory cytokine release 
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Finn, postulated that menstruation could be regarded as an inflammatory 
process(6), as there is a dramatic increase in the numbers of lymphomyeloid cells 
identified in the endometrium, prior to menstruation. 
The endometrial granular lymphocytes increase from proliferative to secretory 
phase. Other inflammatory cell found in substantial numbers includes eosinophils, 
macrophages and neutrophils, whereas T and B cells  present, are  in low numbers. 
Steroid hormones possibly modulate  migratory cell influx via the chemokine action. 
Neither oestrogen receptors (ER) nor progesterone receptor (PR), have been 
found in the leucocytes , in the human endometrium, and so  their effects on leukocytes 
may be only indirect. 
TISSUE REPAIR 
As early as 36 hours after the onset of  bleeding due to menstruation, repair of the 
endometrium begins. However the desquamation is still in progress, due to the very focal 
nature of the degradative and repair processes (7).Regeneration is complete by 140 hours.  
The menstrual fluid is composed of autolysed endometrium rich in inflammatory 
exudates, RBCs and proteolytic enzymes(8). Plasminogen has fibrinolytic action, that 
prevents clotting of menstrual fluid and facilitates the expulsion of the degenerated tissue. 
The local balance between the fibrinolysis and  clotting, controls the amount of bleeding. 
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Table 3: CAUSES OF ABNORMAL UTERINE BLEEDING 
Pelvic Uterine fibroids 
Adenomyosis 
Endometrial polyps 
Pelvic infection 
Endometrial hyperplasia 
Endometrial adenocarcinoma 
Intra uterine device 
Uterine vascular malformations 
Myometrial hypertrophy 
Systemic Coagulation disorders(thrombocytopenia,  Von 
Willebrand disease) 
Hypothyroidism, 
SLE, Chronic liver failure 
 
Functional Dysfunctional uterine bleeding 
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Table 4: MEDICAL DISEASE ASSOCIATED WITH MENORRHAGIA 
ENDOCRINE DISEASE Thyroid dysfunction 
Pituitary/Adrenal abnormalities 
HAEMATOLOGICAL DISEASE Coagulation disorders 
Platelet abnormalities 
Sickle cell anemia 
AUTO-IMMUNE DISEASE SLE 
HEPATIC, RENAL AND 
CARDIAC DISEASE 
Liver disease 
Renal disease 
Cardiac disease 
METABOLIC  DISEASE Gaucher’s disease 
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GENITAL TRACT BLEEDING- NON – UTERINE CAUSES: 
1. Atrophic vaginitis 
2. Vulval causes 
i. Vulval  intra epithelial neoplasia 
ii. Carcinoma vulva 
iii. Skin lesions 
3. Lesions in the vagina 
4. Trauma 
5. Foreign body 
 
FIGO CLASSIFICATION SYSTEM (PALM-COEIN) FOR ABNORMAL 
UTERINE BLEEDING (9) 
This is an universally accepted system of classification . This new classification 
including contributions from an international group of clinician-investigators from six 
continents and over 17 countries, proposes a new system for the classification of 
abnormal uterine bleeding.  
There are nine main categories, are arranged according to the acronym PALM-
COEIN. Polyp; Adenomyosis; Leiomyoma; Malignancy and  Hyperplasia. 
Coagulopathy;  Ovulatory dysfunction;  Endometrial;  Iatrogenic; Not yet classified. 
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Figure 1: FIGO CLASSIFICATION OF AUB 
                 
 
The PALM entities are structural, discrete, measured visually by imaging  or by 
histopathology;  The COEIN  group is non structural; related to those not defined by 
imaging or histopathology. 
 
The term “DUB”, used earlier, for diagnosis in the absence of other systemic or 
locally definable structural cause, should be abandoned and should not be included in the 
system. 
POLYP(AUB-P) 
This comprises a variable vascular, glandular, and fibromuscular and connective 
tissue component and are often asymptomatic, but can contribute to AUB (10). Usually, 
they are benign, but a minority may have atypical or malignant features.(11) 
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ADENOMYOSIS (AUB-A) 
Prevalence varies from 5% to 70% (12). The relationship between adenomyosis 
and the genesis of abnormal bleeding is unclear. It is proposed that sonographic criteria 
for adenomyosis comprises the minimum requirements for assigning an individual the 
diagnosis of adenomyosis  in the PALM-COINE classification(13). The sonographic 
appearance is partly related to the  presence of endometrial tissue in the myometrium  and  
hypertrophy. 
LEIOMYOMA (AUB-L) 
The prevalence is upto 70% in Caucasians. Due to the spectrum of size and 
location and the variable number of lesions in a given uterus it has a separate 
categorization in the system. Many leiomyomas are asymptomatic. Several issues like, 
the relationship of the leiomyoma to the endometrium and serosa; the uterine location of 
the leiomyoma (upper segment, lower segment; cervix, anterior, posterior, lateral); the 
size of the lesions; the number, were considered in the classification system.(14) 
The primary classification system reflects only the presence or absence of one or 
more leiomyomas; The seconday system distinguishes leiomyomas involving the 
endometrial cavity(submucousal) from others, as submucousal is considered most likely 
to contribute to the genesis of AUB. 
The tertiary classification system is a design for subendometrial or submucosal  
leiomyomas. 
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Figure 2 : Leiomyoma subclassification 
 
 
The size of the uterus, single longest measurement, the location and estimated number of 
leiomyomas are not included  in the classification. 
 MALIGNANCY AND HYPERPLASIA(AUB-M) 
The potential causes of AUB,  include atypical hyperplasia and malignancy , and 
this should be considered in the women of reproductive age group. 
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COAGULOPATHY(AUB-C) 
Von Willebrand disease(15),  is the systemic disorders of hemostasis,  diagnosed 
in approximately 13% of women with HMB.  Some women may require chronic 
anticoagulation as an intervention, required to preserve life; these patients on these drugs 
present with AUB, which may or may not respond to oral medications. 
OVULATORY DYSFUNCTION (AUB-O) 
Any disorder of ovulation, can present as menstrual abnormalities – which could 
range from amenorrhea, to extremely HMB requiring intervention. Ovulatory disorders 
(endocrinopathies) like polycystic ovary syndrome, thyroid disorder which includes 
hypothyroidism, hyperprolactinemia, mental stress, obesity, anorexia, weight loss or 
extreme exercise . 
ENDOMETRIAL (AUB-E) 
There may be a primary disorder of “hemostasis”, where evidence has 
demonstrated deficiencies in local production of vasoconstrictors such as endothein-1 and 
prostaglandin F2α. Accelerated lysis of endometrial clot because of excessive production 
of plasminogen activator has also been demonstrated (16). 
Increased production of substances that promote vasodilatation, e.g. PGE2 and 
Prostacyclin I₂ has been known to cause increased uterine bleeding (17). 
Retrospective evaluation does not reveal any relationship of endometritis with 
AUB, but there are data indicating a relationship between subclinical Chlamydia 
trachomatis and AUB (18). 
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IATROGENIC (AUB-I) 
This includes 
a. Intrauterine systems, either medicated or inert. 
b. Pharmacologic agents that directly impact the endometrium. 
c.  Interference with blood coagulation mechanisms. 
d. Those influencing the systemic control of ovulation. 
 
Episodes of break through bleeding are related to reduced circulating gonadal steroid 
levels, due to compliance issues, such as missed, delayed or erratic use of pills. Reduced 
levels of estrogens and progestins , due to use of anticonvulsants and antibiotics (e.g. 
rifampicin/griseofulvin), can also cause AUB(19). 
Women on Levonorgestrel-releasing intrauterine system (LNG – IUS), experience 
unscheduled vaginal spotting in the first 3 -6 months (20). 
In a UK study, 10% of new users, of the LNG-IUS, ceased use by the end of the 
first year because of bleeding complaints (21). 
Any agent that impacts serotonin uptake is a candidate for causing ovulatory 
dysfunction and that result in irregular bleeding (e.g. Tricyclic antidepressants) 
Anticoagulants like warfarin and heparin, impairs the formation of an adequate 
“plug”or clot with the vascular lumen, and hence conributes to HMB. 
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NOT YET CLASSIFIED (AUB-N) 
Entities such as endometritis, arteriovenous malformations, myometrial 
hypertrophy need further evidence for classification, into a particular category. 
 
EVALUATION OF ABNORMAL UTERINE BLEEDING 
There may be multiple factors contributing to the AUB, and hence, a patient 
presenting with the symptoms should be diligently investigated. 
a. General assessment 
b. Rule out pregnancy 
c. Evaluate anaemia 
d. Rule out disorders of ovulation 
e. Screening for systemic disorders if required 
f. Rule out anticoagulation therapy. 
g. Adequate endometrial sampling, if suspicious of atypical     hyperplasia or 
carcinoma. 
h. Abdominal examination 
i. Palpate to rule out fibroid uterus 
A. Examination of the vulva and vagina for any gross pathology 
B. Speculum examination – To exclude cervical polyp, tumour and to 
take pap smear. 
C. Bimanual pelvic examination 
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INVESTIGATIONS 
      The latest guidance from the National Collaborating Centre for Women’s and 
Children’s health states that, “ if the history is suggestive of menorrhagia, without 
suspicion of any structural or histological abnormality, treatment can be commenced; 
whereas if the treatment option is levonorgestrel-releasing intrauterine system, other 
investigations should be performed” (22). 
The initial assessment requires the patient to have a combination of 
unpredictability, excessive duration, abnormal volume, or abnormal frequency of menses, 
for atleast the previous three cycles. 
A.  Blood tests –  
Full blood count , which  includes platelets. 
Serum ferritin level if any doubt about iron deficiency anaemia (23). 
Thyroid  function tests – if history/examination suggestive 
Coagulation profile if history of bleeding disorder 
( puberty menorrhagia or family history if present) 
B. Assessment of Uterine Cavity –  
a. Ultrasound 
 This is the first line diagnostic tool to identify structural abnormality 
 Helps to assess size/number/location of fibroids. Transvaginal ultrasound 
results in high quality image and improves predictive value(24). 
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 Saline infusion sonography detects submucous fibroids. Endometrial 
thickness <5 mm  in postmenopausal and Endometrial thickness between 
10 – 12 mm in premenopausal needs further evaluation(25). 
b. Endometrial biopsy 
 Endometrial sampling is considered for all women with ultrasonic 
abnormality and those with persistent menorrhagia(26). 
 Outpatient biopsy has high accuracy and the Pipelle endometrial sampler 
is a preferred device. 
 Majority of women investigated for Menorrhagia have ‘normal’ 
endometrium, and so been labeled to have a functional disorder. 
c. Dilatation and curettage 
No longer has a role. 
d. Hysteroscopy 
 Better than ultrasound , at identifying polyps. 
 Performed in the outpatient room, only if ultrasound scan is inconclusive. 
 Normally more painful than transvaginal ultrasound. 
e. Magnetic resonance imaging 
No advantage over ultrasound and hence not done routinely. 
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 Figure 3: Evaluation of Chronic AUB 
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30 
 
Figure 4: Uterine Evaluation in AUB 
 
 
 
The uterine evaluation is in part, guided by a good history, other elements of 
clinical situation, such as age, chronic ovulatory disorder or presence of other risk factors 
for endometrial hyperplasia or malignancy. Evaluation of the uterus should include 
imaging, atleast with a screening transvaginal ultrasound examination(TVUS). 
Even in ideal circumstances, TVUS is not 100% sensitive, as polyps and other 
small leisions may not be picked up(27). 
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MANAGEMENT OF ABNORMAL UTERINE BLEEDING 
The treatment of menorrhagia may be medical or surgical. In one review 60% of women 
referred to the hospital with menorrhagia, had hysterectomy within 5 years(28) 
MEDICAL MANAGEMENT:  
More than 90% of blood loss usually occurs in the first 3 days of menstruation. So 
treatment protocol can be either the first few days, which has an advantage of restricting 
medications only to those days of heavy flow. Anemia should also be adequately treated. 
The three treatment regimen which fit into this are prostaglandin synthetase inhibitors, 
tranexamic acid and ethamsylate.  
a. Hormonal treatments:  
 Synthetic progestogens 
 Combined oral contraceptive pill 
 Danazol 
 Gonadotrophin- releasing hormone(GnRH) analogue. 
 Prostaglandin synthetase inhibitors 
 Inhibitors of fibrinolysis 
 Reducers of platelet fragility. 
SYNTHETIC  PROGESTERONES 
This is the most popular drug prescribed in the United Kingdom and New 
Zealand, for menorrhagia(29). 
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The first report of its use was in 13 women, by Bishop and de Almeida, 1960, and 
they reported subjective improvement in menstrual blood loss in 34 out of 52 treatment 
cycles, and then this regimen was universally adopted. 
A route of administration included, intermittent luteal phase oral  administration 
to intramuscular injection to continuous local administration via intrauterine device. Each 
of these have different efficacy. 
Cyclical administration 
Administered usually in the luteal phase of the cycle. Study of norethindrone 10 mg per 
day 15 to 25 , showed no significant reduction in menstrual blood loss (30). 
British investigators evaluated norethindrone in a dose of 10 mg/day from day 19 to 26 
and found an increase in bleeding volume by 20% compared to decrease of 45% in the 
Tranexemic group(31). 
The Cochrane meta-analysis concluded that luteal phase progestins were less effective 
than tranexamic acid, danazol, progestin- releasing IUD(32). A randomized clinical trial , 
compared use of progestin releasing intrauterine device with oral progesterone from day5 
to day 26 and found a 87% reduction in blood loss in the oral group, but the reduction in 
the volume was less, compared to the ID group(33). In another RCT comparing the same, 
both were effective in the treatment of menorrhagia, but intrauterine levonorgesterel , had 
higher satisfaction and continuation of treatment (76% vs 22%) and hence an effective 
alternative(34). 
Anovulatory women were more likely to be satisfied with the use of cyclical progestins, 
than those with ovulatory cycles. 
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CONTINUOUS SYSTEMIC ADMINISTRATION 
Studies of depoprovera demonstrate that by 1 year, 80% become amenorrheic(35). 
There are no published data evaluating Depovera in patients with menorrhagia. 
CONTINUOUS LOCAL ADMINISTRATION 
            Progestin-impregnated intra uterine device is in use for nearly 3 decades(36).  For 
women in the reproductive age group, Levonorgestrel intra-uterine system is one of the 
most acceptable medical treatments for menorrhagia 
Reduces referrals to specialists and decreases the need for operative gynaecological 
surgery. 
MIRENA ( LEVONORGESTREL – RELEASING INTRAUTERINE SYSTEM) 
 Mirena  LNG-IUS (levonorgestrel-releasing intrauterine system) consists of a T-
shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) 
around the vertical stem.  
The reservoir consists of a white or almost white cylinder, made of a mixture of 
levonorgestrel and silicone , containing a total of 52 mg levonorgestrel. The reservoir is 
covered by a semi-opaque silicone (polydimethylsiloxane) membrane. The T-body is 32 
mm in both the horizontal and vertical directions. The polyethylene of the T-body is 
compounded with barium sulfate, which makes it radiopaque. A monofilament brown 
polyethylene removal thread is attached to a loop at the end of the vertical stem of the T-
body.  
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Figure 5 : Mirena 
                        
 
 INSERTER  
It is in a sterile pack which is discarded after insertion. Mirena is packaged sterile 
within an inserter. The inserter, which is used for insertion of Mirena into the uterine 
cavity, consists of a symmetric two-sided body and slider that are integrated with flange, 
lock, pre-bent insertion tube and plunger. Once Mirena is in place, the inserter is 
discarded. 
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Figure 6:    Diagram of Inserter 
 
       
   Levonorgestrel USP, (-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-
yn-3-one, the active ingredient in Mirena, has a molecular weight of 312.4, a molecular 
formula of C21H28O2, and the following structural formula: 
Figure 7: Levonorgestrel 
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Pharmacology: 
The initial release is 20µ gms per day till 5 years. This rate decreases to half after 
5 years (37). 
There is a rapid absorption of locally released levonorgestel from the uterine 
cavity, via the capillary network in the basal layer of the endometrium, into the systemic 
circulation. 
Levonorgestrel can be detected within 15 minutes after insertion, reaching 
maximum plasma levels within a few hours. The intrauterine concentration are 1000 
times higher than with a levonorgestrel subdermal implant(38). 
 
Mirena has mainly local progestogenic effects in the uterine cavity.  
Morphological changes of the endometrium, include 
a)Stromal pseudodecidualization,  
b) Glandular atrophy,  
c) Leukocytic infiltration, and  
d) Decrease in glandular and stromal mitoses.  
e) Alteration in the cerivical mucus and uterotubal fluid  
f) Inhibits sperm migration 
37 
 
g) Adverse effect on the sperm motility an function inside the genital tract, 
preventing fertilization. 
h) Vascular changes – Decrease in mean vascular density and increase in mean 
vessel area(39). 
i) Ovulation is suppressed by reducing the pre-ovulatory surge in luteinizing 
hormone. 45% of the cycles were ovulatory at the end of one year. Most cycles become 
ovulatory from the second year onwards, to reach 75% at the end of 4 years. Presence or 
absence of menstrual bleeding does not reflect ovarian activity. 
 
POST INSERTION EFFECTS: 
Women inserted with IUS, frequently complain of menstrual disturbance. 
Prolonged bleeding for >8 days is seen in 17% of women in the first month of use, falling 
to 3% at the end of 3 months. It takes 6 months on an average to settle in women with 
heavy flow(40). 
Amenorrhea is seen in 17% at the end of one year, increasing to 60% in long term 
users(41). One to two women out of 100 women discontinue IUS because of 
progestogenic symptoms(42). 
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ADVERSE EFFECT(42,43). 
1. Uterine and vaginal bleeding (including spotting, irregular bleeding, heavy 
bleeding, oligomenorrhea and amenorrhea)  
2.  Ovarian cysts 
3. Abdominal/pelvic pain  
4. Vaginal discharge  
5. Nausea/ Headache/ Nervousness.  
6. Vulvovaginitis  
7. Dysmenorrhea/ Back pain  
8. Weight increase  
9. Breast pain/tenderness  
10.       Acne  
11.       Decreased libido /Depressed mood  
 12.       Class II Hypertension 
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REMOVAL OF MIRENA: 
Indications for removal of mirena include-  
• Acquired immune deficiency syndrome (AIDS)  
• Sexually transmitted disease  
• Pelvic infection; endometritis  
• Symptomatic genital actinomycosis  
• Intractable pelvic pain  
• Severe dyspareunia  
• Pregnancy  
• Endometrial or cervical malignancy  
• Uterine or cervical perforation 
 
Mirena is preferably removed at the time of a menstrual period, but if removed otherwise, 
should be advised to avoid sexual intercourse for 7 days before removal(44). 
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CLINICAL STUDIES ON INTRA UTERINE LEVONORGESTREL DEVICE 
1) Menorrhagia (Including Adenomyosis and Fibroid related) 
In 1982, Heikkila et al showed that serum ferritin levels improved in IUS users, 
with normal menstrual blood loss(45).  
Haemoglobin was also found to increase in women with menorrhagia(46). 
In 1990, 20 women with menorrhagia, on IUS, showed a reduction in blood loss 
by 86% in 3 months and 97% in 12 months(47). 
 
Table 5: In 1991, Milsom et al(48), compared the reduction of menorrhagia and found 
At 3 months NSAID Antifibrinolytic IUS 
Reduction in 
blood loss 
20.7% 44.4% 81.6% 
 
At the end of one year, there was a 95.8% reduction in menstrual blood .Amenorrhea was 
found in 35% of women, at the end of 24 months(49). 
Compared to Mefenemic acid(NSAID), LNG reduced the blood loss to just 5 ml 
in women with idiopathic menorrhagia(50). 
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Table 6: Comparison between the IUS and norethisterone (51), group showed: 
In 3 cycles IUS group Norethisterone group 
Reduction in menstrual 
blood flow 
94% 87% 
Wish to continue treatment 76% 22% 
 
 
Table 7: Cancellation of major surgery was noticed in 6 months, after insertion(52): 
At 6 months IUS Controls 
Cancellation of surgery 64.3% 14.3% 
 
In a 5 year follow of patients, with IUS, 42% of patients on IUS ultimately had 
hysterectomy. However, use of IUS was cheaper than hysterectomy(53).  Health related 
quality of life and psychosocial well being was the   same in both the IUS and the 
hysterectomy groups. 
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Table 8: Minimally invasive surgery like Endometrial resection or ablation was compared 
with IUS use(54). 
At 12 months of use IUS Endometrial resection 
Pictorial blood loss 
assessment chart(PBAC) 
79% reduction 89% reduction 
Amenorrhea/infrequent 
bleeding 
65% 71% 
Satisfaction High High 
 
Between Thermal balloon endometrial ablation and IUS, both were found to be equally 
effective(55). 
Cochrane systematic review concluded hysterectomy reduced menstrual bleeding 
at one year, more than the other medical treatments, but IUS, was found to be equally 
effective in improving the quality of life(56). 
IUS has an effect on the haemostatic and fibrinolytic inhibitor systems in women 
with menorrhagia and demonstrates high expression of fibrinolytic inhibitors and 
urokinase-type plasminogen activator in the endometrium, without altering the systemic 
haemostasis. Therefore IUS is used to treat inherited bleeding disorders(57).  
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In women with fibroid related problems(58), LNG-IUS 
 Reduces the need for surgery 
 Reduces blood loss 
 Causes rise in serum ferritin  
 Causes rise in haemoglobin 
 No significant effect on the reduction in uterine size and fibroid volume. 
In women with Adenomyosis related menorrhagia,  IUS may reduce menstrual blood loss 
significantly, but more studies are required(59). 
2. Endometriosis 
About 21% of women being investigated for infertility, are found to have 
endometriosis. However atleast 50% of women in the United Kingdom complain of 
moderate dysmenorrhea. 
Table 9: On following up the insertions of IUS(60): 
In 36 months Before insertion of IUS After insertion of IUS 
Dysmenorrhea 60% 29% 
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IUS improved the disease staging(61), and reduced pain in those with Rectovaginal 
endometriosis(62). 
Table 10: In those women, who had IUS inserted post operatively, after conservative 
surgery for endometriosis(63), 
 
 
 
 
 
Comparing women with IUS and depot gonadotrophin-releasing hormone 
analogue, for controlling pain related to endometriosis,  there was a rapid improvement in 
those with severe endometriosis, but women with IUS had a higher bleeding score 
throughout 6 months of the study, but the quality of life was similar, in both the 
groups(64). 
 
How does IUS improve the endometriosis- related pain? (65). 
 Causes alteration in the production of local tissue factors 
 Blockage of endometrial DNA synthesis 
12 months post op. Inserted IUS Expectant treatment  
Recurrence of moderate 
to severe dysmenorrhea 
10% 45% 
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 Blockage of mitotic activity 
 Endometrial atrophy 
 Higher level of peritoneal fluid levels of levonorgestrel 
 Anovulation at 3 months, till atleast 12 months, after which it becomes   
ovulatory. 
Long term randomized controlled trials are required to prove the additional advantages of 
a treatment lasting for 5 years, with one device. 
 
3. Endometrial Hyperplasia 
Studies show that IUS would cause regression of endometrial hyperplasia. First 
study was published in 2003, where IUS caused complete regression of endometrial 
hyperplasia(66).  Cell apoptosis and downregulation of oestrogen and the progesterone 
receptors was found to be the mechanism of action in women with endometrial 
hyperplasia(67). 
In the treatment of early stage I endometrial cancers, caution is advised, as 
complete histological regression is not seen in all treated(68). Hence it is important to 
investigate women with persistent heavy menstrual bleeding appropriately. 
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4. Contraception 
Mirena is an effective contraceptive for 5 years. It is a very acceptable and 
immediately reversible contraceptive, with a 3 year continuation rates of 75-82%(69). 
However, if its effectiveness fails, there is chance of ectopic pregnancy in 1 in 20 
women. Overall incidence of ectopic is one in 1000 over a 5 year period. 
 
COMPLICATIONS 
a) Expulsion- Partial or Complete . Occurs in 1 in 20 women in 5 years(70) 
b) Uterine perforation 
c) Ovarian cysts- Surgical treatment is rarely needed. 94% resolves     
spontaneously, in 6 months(71). 
d) Risk of pelvic inflammatory disease is low, less that 1 per 100 women. 
Risk is high only in the first 20 days after insertion. 
 
COSTS 
The American data suggests that IUS is the most cost effective therapy for 
Abnormal Uterine Bleeding(72). 
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OTHER FORMS OF MEDICAL MANAGEMENT 
Cyclical Hormonal Regimens- This is prescribed by 11% of general practitioners. 
Overall reduction in mean blood loss was form 158 ml to 75 ml.  The fear of 
thromboembolic disease in older women makes it unpopular. The third generation OCPs 
have increased risk of venous thromboembolism. OCPs act by making the endometrium 
inactive, reducing the endometrial prostaglandin synthesis and altering uterine 
fibrinolysis. The common side effects are, headache, migraine, nausea, acne, weight gain, 
breast discomfort, hypertension, thrombosis,  stroke and jaundice. 
Prostaglandins – NSAIDs reduces blood loss by inhibiting endometrial prostaglandin 
synthesis. The reduction ranges from 22% to 46%.  It is usually prescribed with oral 
contraceptives. The additional benefit is that NSAIDs reduces dysmenorrheal and 
headaches during menstruation. The side effects include nausea, vomiting, gastric 
discomfort, diarrhea, headache, bronchospasm, thrombocytopenia and hemolytic 
anaemia. 
Antifibrinolytic agents: Tranexamic acid, an inhibitor of fibrinolysis, and has showed a 
mean reduction in blood loss from 295 ml to 155 ml. The reduction in blood loss was 
44% with tranexamic acid. The beneficial effect lasts only during the treatment cycle. 
The side effects include, nausea, vomiting, diarrhea, dizziness, visual disturbances, 
cerebral thrombosis. 
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Androgens: 
Danazol is a synthetic androgen with anti-oestrogenic and antiprogestogenic 
activity. It acts by inhibiting pituitary gonadotrophins and by local endometrial effects. 
The endometrium becomes thinned out, and the menstruation decreases, leading to 
amenorrhoea in large doses, whereas small doses causes only decrease in bleeding during 
menstruation. Overall there was a reduction of MBL of 60%, when compared to NSAIDs 
with a 20% reduction in blood loss. 
Androgenic side effects are weight gain, muscle cramp , skin rashes, voice 
change, bloating and reduction in breast size. 
GnRH agonists: Causes hypo-oestrogenic state and endometrial atrophy. MBL 
reduced from 131 ml to 11 ml after 3 treatment cycles., 80% of patients being satisfied.  
Side effects include menopause like symptoms and vaginal dryness. Long term 
treatments carry risks of osteoporosis.  
Patients who are suffering from abnormal uterine bleeding also usually have 
anaemia, and hence all patients, should be prescribed, oral iron, folic acid, protein and 
vitamin supplementation. 
First generation endometrial ablation includes:  roller-ball endometrial ablation, loop 
endometrial resection and Laser endometrial ablation.  
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This is performed early in the proliferative phase of menstruation, when the endometrial 
linning is thin. A sharp or suction curettage is done immediately before ablation. 
Pretreatment with GnRH, danazol, progesterones, or combined oral contraceptive pills, 
makes the endometrium thin, and has the advantage of good hysteroscopic view. 
Endometrial laser ablation-  Normal saline is used as the distending fluid of 
choice. There are two techniques; The dragging technique and the blanching technique. It 
is important that the tip of the laser fibre is in view and it should move rapidly, to avoid 
excessive coagulation and thermal necrosis. The disadvantages are that it is expensive, 
slowest of all techniques, greater risk of fluid overload and need for safety guidelines. 
Roller ball endometrial ablation- The energy used for this is electrosurgical. It 
is available in 2.5 mm and 5 mm diameter and electrocoagulation is the principle behind 
the procedure. It is easy to perform, has shorter operating time, less risk of perforation 
and haemorrhage. The most important disadvantage is , that there is no sample for 
endometrial histology. 
Loop endometrial resection- Transcervical resection of the endometrium is an 
effective method of treating patients with dysfunctional uterine bleeding.  It can be 
combined with hysteroscopic myomectomy in case of menorrhagia with submucous 
fibroids.  It provides tissue for histology, suitable for a thick endometrium; it however 
requires skill and the disadvantage is that it has a greater risk of uterine perforation. 
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Second generation endometrial ablation includes : 
a) Cryotherapy- This is a non hysterscopic technique which uses cold 
temperatures for the purpose of destruction of the endometrium. The cryoprobe is cooled 
to -90.C, using liquid nitrogen or a gas mixture to create ice balls. 
b) Thermal ballon ablation – Endometrial destruction is by conducted heat. 
It is quick to perform and has significant reduction in the menstrual loss. 
c) Microwave endometrial ablation- the local heating effect causes 
coagulation and the depth of the endometrium should be more than or equal to 10 mm. 
Pain scores and bleeding significantly reduced.   
d) Electrode:mesh – NovaSure- This consists of a disposable hand piece 
and a computerized generator. The amenorrhea rate is around 65%. 
e) Hydrothermablation- In this procedure, heated saline circulates freely 
within the cavity, introduced through the hysteroscope.  The patients were discharged 
after 2 hours of the procedure.  
f) Laser interstitial hyperthermy- This is a blind procedure, where the 
temperature within the uterine cavity reaches 102.C.  
g) Photodynamic therapy- Topical photosensitizing agent is taken by the 
endometrium, reach upto the basalis layer. Further studies required.  
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Hysterectomy-  
It is 100% successful in treating abnormal uterine bleeding, and the satisfaction 
rates after hysterectomy are very high. Abdominal compared to laparoscopic surgery 
demonstrated no difference in the quality of life. Whenever possible, vaginal 
hysterectomy should be performed. 
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METHODOLOGY 
 
     This study was approved by the Research Committee and Institutional Review 
Board (Ethics Committee) of Christian Medical College, Vellore. The study was 
reviewed in detail by the research  committee and was accepted for follow up of patients 
for whom Mirena, was inserted between 2007 to 2011. 
 
Sample size  
Studies have proved that  the menstrual blood loss, is reduced by 95% by 6 months and 
97% at the end of one year, after insertion of Mirena.  Hence the sample size was 
calculated, with a precision of 3%, and desired confidence level of 95%, as 124. 
                   
Confidence Interval(%) Sample size(n) 
90 87 
95 124 
99 215 
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Recruitment 
The records on insertion of Mirena, were obtained from the procedure room, in 
the Out patient Department , Obstetrics and Gynaecology,  and the hospital numbers of 
the patients , who had insertion of  Mirena, from the year 2007 to 2011 were collected.  
 
a. Participants:  
INCLUSION CRITERIA 
1. Married women 
2.  Age group (18-50 yrs) 
3.  With Mirena inserted for Menorrhagia , Endometriosis, Adenomyosis , 
Firboid and Endometrial hyperplasia.  
 
EXCLUSION CRITERIA 
1. Age above 50 yrs 
2. With history of malignancy 
3. Where  Mirena was inserted  for Contraception alone. 
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Those patients who had a contact number were contacted  over phone and  
enquired about insertion of  Mirena,  the  symptoms they presented with,  reason for 
insertion, number of days of bleeding, whether excessive,  and whether associated with 
pain.  The survival analysis was done and patient asked whether Mirena was insitu , 
removed or expelled. 
Those patients who had inserted Mirena,  and continued to use for one year and 
above, and  were willing to be followed up, were sent by registered post, questionnaires 
translated to hindi, and the patients allowed to fill the questionnaire, after a written 
consent.  
Those patients who had inserted Mirena,  and continued to use for one year and 
above,  and were willing for a telephonic interview, were explained about the study and  
an oral consent obtained, for follow up. 
The general  proforma (Annexure II), which includes general information about 
the patient, including the indication, bleeding pattern, associated symptoms, haemoglobin 
before and after one year of insertion, associated comorbidities, whether ultrasound and 
endometrial biopsy  were done, were analysed. 
 
Menorrhagia was assessed by using the Uterine Fibroid Symptom and Health-
Related Quality of Life Questionnaire (UFS-QOL) (Annexure III) ,  which includes a 
set of 37 questions. This proforma contains questions which assesses the following: 
a) Symptom severity (8 questions) 
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b) Concern (5 questions) 
c) Activities (7 questions) 
d) Energy/Mood ( 7 questions) 
e) Control (5 questions) 
f) Self Consciousness ( 3 questions) 
g) Sexual function (2 questions) 
 
 UFS-QOL proforma before and after one year of insertion were filled separately, 
and the health related quality of life compared. Scoring ranged from 1 to 5;  a score of 5 
was given to the most distressing symptom, and the total score calculated. 
SF-36  questionnaire (Annexure IV) 
     The SF-36 questionnaire contains a set of 36 questions. The questionnaire was 
used to assess the quality of life in all patients inserted with Mirena, unlike UFS-QOL, 
which was used in patients only with menorrhagia. The SF-36 questionnaire was used to 
assess the following: 
 
a) Physical functioning 
b) Role limitations due to physical health 
c)  Role limitations due to emotional problems 
d) Energy/ Fatigue 
e) Emotional well being 
f) Social functioning 
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g) Pain 
h) General health 
The positive answers were given a maximum score of ‘100’, and the most 
negative answer a score of ‘0’. 
Visual analogue scale (VAS) (Annexure V) 
The improvement in pain for Endometriosis, was assessed by the  Visual analogue 
scale (VAS) , which was used for Pain analysis, in all patients complaining of pain. 
Scores of pain before insertion of Mirena and one year afte Mirena, were 
obtained.  Both these percentages were compared and the improvement calculated, and 
significance derived at. 
Clininical global impressions scale (CGI SCALE – GLOBAL IMPROVEMENT  ITEM) 
(Annexure VI) 
The degree of satisfaction was followed up using the CGI Scale. The maximum 
level of satisfaction  was scored 7  and who were very much dissatisfied, were scored 1. 
Statisical Analysis of data: 
Paired t test was used for continuous variables  with a  95% confidence interval 
and significance were calculated . 
Survival analysis was also done and the reason for removal was compared by 
Tarone-Ware method. 
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RESULTS 
The total number of patients who had insertion of Mirena from 2007 to 2011 were 
353 patients, out of which only 177 patients were followed up. 
 
Baseline characteristics of patients followed up after insertion of Mirena. 
The age of the patients who had insertion of Mirena were between 25 to 50 years 
of age, the mean age being 38.57 yrs. 
The mean BMI of patients who had insertion of Mirena was 25.96.  
Table 11 : Baseline characteristics 
 
 
 
 
 
 
 
 
Variables Mean±SD  n% 
Age(years)   38.5 ± 5.7 
Height(cms) 154.7± 5.7 
Weight(kg)    62.2± 11.7 
BMI kg/m2  25.96± 4.5 
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Table 12: Year of Insertion of Mirena 
 
 
 
 
 
 
 
 
 
 Parity in 49% of patients  who had insertion of Mirena was 2.  
Number of women who had  2 children were 51%. 
 
 
 
 
Year of 
insertion  
Number of patients 
inserted Mirena 
Number of patients 
followed up 
2007 
23 8 
2008 
32 19 
2009 
67 20 
2010 
123 64 
2011 
108 66 
Total 
353 177 
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Table 13:  Number of living children for people with mirena insertion. 
 
No. of children n % 
O 8 4.6 
1 51 29.1 
2 90 51.4 
3 18 10.3 
4 5 2.9 
5 3 1.7 
 
 
 
Figure 8 : Place distribution 
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Table 14: The number of patients who completed the study were 110. 
 
Completed    study 110 
Expelled 36 
Removed 19 
Improved but not 
contactable 
09 
Died 03 
Total 177 
 
 
Table  15: Type of Interview conducted for follow up 
 
 n % 
Telephonic 117 74.1 
Direct 17 10.8 
Postal 24 15.2 
 
Dysfunctional uterine bleeding was the reason for insertion in almost 50% of patients. 
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Table 16: Reason for insertion of Mirena 
 
Reason for 
insertion 
n % 
DUB 89 50.3 
Endometriosis 38 21.5 
Adenomyosis 29 16.4 
Fibroid uterus 21 11.9 
 
 
Figure 9: Reason for insertion of Mirena. 
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Symptoms prior to insertion of mirena: 
 
88% of patients had menorrhagia, prior to insertion. 
 
Table 17: Primary symptom before insertion of Mirena 
Indication n % 
Menorrhagia 142   80.2 
Dysmenorrhea   35   19.8 
 
Table  18:Secondary symptom before insertion of Mirena 
 
Secondary indication n % 
Menorrhagia 16 16.8 
Dysmenorrhea 75 78.9 
Dyspareunia 4 4.2 
 
40.8% of Women who had insertion of Mirena were Sterilised. 
 
Table 19: Pattern of bleeding before Mirena- Regular 
 
Regular 
cycles 
n % 
Yes 138 78 
No 39 22 
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89.3% of patients  had excessive flow during their menstrual period, and the 
number of days of bleeding ranged between 1 to 15 days, the average being 7.5 days. 
 
 
Table 20: Patients who had dysmenorrhea , before insertion of Mirena 
 
 
Dysmenorrhea n % 
Yes 109 61.9 
No 67 38.1 
 
53.1 % of patients had their haemoglobin checked prior to insertion of Mirena; whereas 
only 13.7% of patients had their haemoglobin checked, after one year of insertion of 
Mirena. 
 
Table 21: Haemoglobin before and one year after insertion of Mirena. 
 
 Mean±SD 
Preinsertion 
Hb(gm%) 
10.4±2.4 
Hb after 1 
year(gm%) 
11.5±2.3 
 
27.4% of patients were treated for anaemia; 29.1% received iron supplementation; 
23.3% of patients were on treatment for hypothyroidism. 
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Figure 10: The comorbidities seen among the patients who had insertion of Mirena. 
 
 
 
 
Figure 11:  Number of comorbidities seen among the patient who had insertion of  
Mirena 
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Ultrasound – 75.6% of patients who had insertion of Mirena had a screening ultrasound. 
Endometrial biopsy- Only 23.3% of patients had an endometrial biopsy done, for  
evaluation. 
 
 
Table 22:  Number of patients with a histopathological diagnosis of Endometrial     
Hyperplasia 
 
 
 
 
 
 
Figure 12: Patients with histological diagnosis of endometrial hyperplasia 
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Table 23: Patients on Mirena who were prescribed additional Medical therapy 
 
Medical therapy n % 
Progesterone 33 18.6 
NSAIDs/Tranex 25 14.1 
OCP 67 37.9 
Danazol 03 1.7 
None 49 27.7 
 
 
Figure 13: Patients who received additional therapy 
 
 
 
 
 
0 50 100 150 200 
Progesterone 
NSAID/Tranex 
OCP 
Danazol 
None 
Total 
Percentage 
Frequency 
67 
 
Table 24: Women who had Improvement of symptoms after one year of insertion of 
Mirena 
 
Improvement n % 
Yes 118 68.6 
No 54 31.4 
 
 
Number of months in which improvement occurred was between 3 to 12 months, the 
average being 5.36 months. 
Table 25:  Pattern of menstruation, after one year of insertion of Mirena 
 
 
 
 
 
Figure 14: Pattern of bleeding after Mirena 
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Table 26: Side effects reported by women after insertion of Mirena. 
 
 
 
 
 
 
 
 
Table 27: Patients who had Voluntary Removal of Mirena 
 
Voluntary 
removal 
n % 
Yes 25 14.3 
No 150 85.7 
 
Figure 15: Patients who had voluntary removal of Mirena 
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Pelvic pain 01 5.3 
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Table 28-. Number of months within which Mirena was removed and expelled 
 
No. of months Mean±SD 
Removal 16.68±14.88 
Expulsion 6.55±7.39 
 
Of all the patients who voluntarily removed Mirena, 76% of the patients removed within 
one year of insertion. 
 
Figure -16: Reason for removal of Mirena 
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Table 29: Number of women who spontaneously expelled Mirena 
 
Expulsion n % 
Yes 41 23.4 
No 134 76.6 
 
 
Table 30: Number of Women who had reinsertion of Mirena after expulsion or 
removal 
 
Reinserted n % 
Yes 04 6.3 
No 59 93.7 
 
 
 
Table  31:  If Mirena was not reinserted what was the treatment taken 
 
Treatment  n % 
Medical management 33 55 
Hysterectomy 27 45 
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Table 32 : CGI SCALE FOR SATISFACTION AFTER MIRENA 
 
Satisfaction n % 
Very much dissatisfied 1 0.9 
Much dissatisfied 4 3.7 
Neither satis/ Nor dissatisfied 1 0.9 
Minimally satisfied 12 11.2 
Much satisfied 16 15.0 
Very much satisfied 73 68.2 
 
 
 
Table 33: Final inference on satisfaction 
 
Satisfaction n % 
Satisfied 91 83.5 
Minimally satisfied 12 11.0 
Undecided/worse 06 5.5 
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Table 34: VISUAL ANALOGUE SCALE  FOR PAIN ANALYSIS:  
Comparing pain before insertion of Mirena with one year after insertion of Mirena, the 
mean pain reduced from 86.62% to 14.22%. 
VAS Mean  
Before insertion of 
Mirena 
86.62%±20.31 
One year after 
insertion of Mirena 
14.22%±20.10 
 
 
Table 35: Visual analogue scale – Paired ‘ t’ test 
 
 VAS  Mean± SD Mean Change 95% CI P value 
Before  86.2±20.3  
     72.40 
 
66.10 to 78.70 
 
<0.01 After  14.2±20.1 
 
Table 36: UFS –QoL Symptom severity  (Menstrual symptoms), before Mirena and 
one year after Mirena, shows a significant reduction of symptoms. 
 
Symptom 
severity 
Mean ±SD Mean change 95% CI P value 
Before  25.43 ± 4.55 13.87 12.67 to 15.06 < 0.01 
One year After  11.56 ± 5.65 
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Table 37: UFS – HRQL( Uterine fibroid symptoms, health related quality of life) 
 
UFS-HRQL Mean ±SD Mean 
change 
95% CI P value 
Concern 
Before 
After 
17.53  ± 4.49 
6.44 ± 3.30 
 
11.09 
 
10.01 to 12.76 
 
< 0.01 
Activity 
Before 
After 
 
25.98 ± 4.75 
9.80 ± 5.36 
 
16.18 
 
14.68 to 17.67 
 
< 0.01 
Energy/Mood 
Before 
After 
 
26.42 ± 4.77 
10.72 ± 6.56 
 
15.70 
 
14.11 to 17.28 
 
< 0.01 
Control 
Before 
After 
 
19.26 ± 3.76 
7.48 ± 4.78 
 
11.78 
 
10.51 to 13.04 
 
< 0.01 
Self conscious 
Before 
After 
 
7.67 ± 2.50 
5.15 ± 2.30 
 
2.52 
 
1.98 to 3.05 
 
< 0.01 
Sexual function 
Before 
After 
 
7.01 ± 2.29 
3.51 ± 1.97 
 
3.49 
 
2.92 to 4.06  
 
< 0.01 
HRQL  
Before 
After 
 
1.03 ± 16.70 
43.07±20.92 
 
6.079 
 
55.17 to 66.28 
 
< 0.01 
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Table 38 : UFS –QoL analysis in toto including analysis of menstrual severity and 
health related quality of life 
 
 
UFS total Mean ± SD Mean change 95%  CI P value 
Before Mirena 
 
One year after 
Mirena 
 
 
129.23 ± 19.00 
 
54.63 ± 25.86 
 
 
74.60 
 
68.11 to 
81.08 
 
 
< 0.01 
 
 
 
Table 39: Haemoglobin values before and after one year of insertion of Mirena 
 
 
 Mean ± SD Mean Change 95% CI P value 
Before Mirena   9.80 ± 2.39 -1.55 -3.09 to -0.03 0.049 
One year after 
Mirena 
11.35 ± 2.59 
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Table 40: SF 36- Scoring of quality of life after one year after insertion of Mirena. 
 
SF 36 – Scoring (Percentage) Mean ± SD 
 
Median (IQR) 
 
Physical 88.5   ± 17.86 100 (80,100) 
Role- Physical health 86.57 ± 28.68 100 (100,100) 
Role- Emotional 86.72 ± 30.20 100 (100,100) 
Energy 73.98 ± 20.29 80   (65,90) 
Emotional 77.07 ± 19.42 84   (72,92) 
Social 89.0   ± 21.32 100 (87.5,100) 
Pain 83.63 ± 25.59 95   (77.5,100) 
General health 78.10 ± 23.16 90   (70,95) 
 
 
Table 41: Overall survival time (Time of discontinuation of Mirena) 
 
Median (Months) 95% CI 
6.00 4.0 to 7.9 
 
 
The median duration of Mirena removal was 6 months (4 to 7.9). 
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Figure 17: Survival Analysis 
 
 
 
Table 42: Reason for Voluntary Removal of Mirena 
Reason for Removal Median (Months) 95% CI P value 
Side effects 24.0 5.28 to 42.71  
0.059 No improvement 9.0 5.56 to 12.43 
Hysterectomy 36 0.073 
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The reason for Mirena Removal were Side effects, No improvement and 
Hysterectomy and the duration were 24, 9 and 6 months respectively; yet the difference is 
not found to be statistically significant. 
  
Figure 18 : Survival Functions (Reason for removal) 
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DISCUSSION 
The term abnormal uterine bleeding is used for both ovulatory and anovulatory 
bleeding. Abnormal uterine bleeding affects 10 – 30% of women of the reproductive age 
group, and about 50% of women in the perimenopausal age group. 
The average length of the cycle is 28 days, the average duration is 4 days and the 
average blood loss during menstrual cycle is between 30 to 40 ml per cycle. The 90
th
 
percentile for blood loss during menstruation was 80 ml, and anaemia was significantly 
increased in women with a loss of greater than 60 ml. Loss of more than 80 ml per 
menstrual episode is defined as menorrhagia.   
However 20%  of women who have documented normal flow, complained of 
menorrhagia, and seeked treatment(2). 
The physician may not be able to assess the volume of blood lost during menstrual 
cycle from the history. The different methods by which the menstrual blood loss can be 
assessed are as follows: 
Subjective assessment- 
Direct measurement of the menstrual blood loss is the only reliable way to diagnose 
menorrhagia. The other way of assessment is by the rate of change of sanitary pads during the 
flow and the total number of pads and tampons used (75). 
It is an inaccurate method and there was no correlation between self assessment, 
number of sanitary pads used, duration of the menstrual period and the objective menstrual 
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blood loss (7). Only 44% of women complaining of menorrhagia, had a menstrual blood loss 
of more than 80 ml. 
 
Objective measurement-  
The exact amount of haemoglobin lost is measured by the alkaline hematin method. 
The modifications of the alkaline hematin method  for the diagnosis of heavy menstrual blood 
loss improves the  recovery rate from 89% to 98%, and so it can used as a reliable 
method(74). Menstrual blood is extracted by soaking the sanitary pads in 5% sodium 
hydroxide and haemoglobin converted to alkaline hematin; it is centrifuged and the optical 
density measured by spectrophotometry, and compared with the patient’s venous blood. But 
this test is laborious, costly and causes inconvenience to the patient, though it is accurate. 
When there was a fall in haemoglobin, with increase in menstrual blood loss, a rise in 
the ferritin levels were noticed, but was relevant only if the menstrual blood loss was more 
than 120 ml/cycle(76). 
Indirect (semi-objective) measurement –  
Clinical features associated strongly with excessive blood loss are frequency of 
changing sanitary pads, passage and the size of clots and flooding. Low ferritin level picks up 
60% of women, with loss more than 80 ml(77). 
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 The menstrual pictogram provides a simple way of measuring the blood loss.  
Pictorial blood  assessment charts may not accurately reflect the hygiene products used (73). 
Evaluation of this chart by further studies, debated its validity.  
The NICE guidelines (National Institute for Health and Clinical Excellence), does not 
routinely recommend assessment of blood loss in menorrhagia(78). 
The ACOG does not recommend  blood count or testing for thyroid hormones for 
women with excessive bleeding(79).  Evidence based guidelines from the Royal College of 
Obstetricians and Gynaecologists, recommend,” these tests, and thyoid and bleeding disorder 
evaluation should be done if there are clinical or historical features”(80). 
Menorrhagia can result in severe anaemia. 58% reported a history of anaemia, and 
89% of them received oral iron therapy(81). 
Treatment of menorrhagia results in substantial improvement in the quality of life. 
Medical therapy available for menorrhagia are Non steroidal anti inflammatory drugs, 
antifibrinolytic drugs, progestogens, oral contraceptives and danazol. All these therapies are 
partially effective in  reducing  the menstrual blood loss. The choice of medical treatment is 
the choice of the individual. Local LNG-IUS ranks much higher than all other medical 
treatments, when the effectiveness, side effect and acceptability are taken into account.  
The other forms of treatment include endometrial resection/ablation and hysterectomy. 
Hysterectomy is a definitive treatment , but the risk of surgical morbidity and the cost 
involved should be considered.  
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Studies comparing the long term efficacy of  LNG-IUS and Endometrial resection  
,show that in both the treatments there was a reduction in the menstrual bleeding.  
The NICE in the UK, has recommended that Mirena, should be considered as the first 
line of treatment, if no structural abnormalities are detected. Mirena proved superior to  oral 
treatment in achieving  normalization of  blood loss and also in frequency of side effects. 
The reduction in menstrual blood loss was almost 94% in 3 cycles and the 
continuation rate was 76%.  
At the end of 6 months  of use of Mirena, 64.3% of patients cancelled their surgery.  
In a follow up study for 5 years, 42% of patients ultimately had hysterectomy.  
Expulsion was low occurring in 1 in 20 insertions. 
The results derived from this study on follow up of patients inserted Mirena, from 
2007 to 2011 are: 
     There were a total of 353 insertions, out of which only about 50% of patients, could 
be followed up.  
The incorrect address, missing phone number were the main drawbacks.  This could 
have been avoided if the same study, could have been done as a prospective study. 
     Comparing the place distribution, it was analysed that, three fourth of the patients 
were from  north India, and almost 50% of the patients of the total number were from the 
West Bengal.  Though the questionnaires were translated into hindi, there was practical 
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problems in the patients understanding the questions, as the questionnaires were elaborate. 
Therefore almost 74% of the patients were conducted telephonic interviews. 
62% of the patients had Mirena in situ for one or more years. While the expulsion rate 
was 20% , the reason probably was that additional medical therapy was not prescribed and the 
flooding probably would have continued leading to expulsion of Mirena.   
The rate of voluntary removal was about 10.7%, and most of the removal were within 
the first 6 months of insertion. This is probably because, the patients did not wait long enough, 
for the onset of its effect. If waited enough with additional medical therapy, to control acute 
symptoms,  they would have improved, and this could have avoided the removal of Mirena. 
     Three patients who had insertion of Mirena for menorrhagia died, due to severe 
comorbidies . (acute myeloid leukemia, valvular heart disease requiring anticoagulation and 
chronic renal failure). 
Dysfunctional uterine bleeding was the most common diagnosis made prior to 
insertion of Mirena. 50% of patients were inserted Mirena for Dysfunctional uterine bleeding 
and 21% for endometriosis. The other reasons include adenomyosis and uterine fibroids, 
causing symptoms. 
Menorrhagia was the primary symptom in 80% of patients and dysmenorrhea was the 
secondary symptom in 78% of patients. Only 4.2% of patients, had complained of 
dyspareunia. 
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a) Among the baseline demographics, the mean age  of the patients was 38.5 years, the 
average BMI was 25.9 kg/m2, the average parity was 2; 40.8% of women were 
sterilized 
b) 78% of patients had regular excessive flow, the average number of days of bleeding 
was 7.5 days, 62% had associated dysmenorrhea.  
c) Haemoglobin prior to insertion was done in 53% of patients with a mean value of 10.4 
gm%; Though the minimum haemoglobin level was 3 gm%, there was one patient 
with a haemoglobin of 17 gm% pre insertion. Only 27% of women were treated for 
anaemia, whereas iron supplementation was given  to 29% of the patients.  
d) 23% of women had hypothyroidism, 30% had diabetes, 39% had hypertension. 15% of 
patients with Rheumatic heart disease, some on anticoagulation had response with 
Mirena. 
e) 75% of the patients had an ultrasound done; 23% of them had endometrial biopsy 
done, of which endometrial hyperplasia, was reported only in 3 patients. 
f) 38% of patients were prescribed oral contraceptive pill and 18.6% were prescribed oral 
progesterones, in addition to Mirena in the first 3-6 months, as additional therapy. 
g) Haemoglobin was done only in 13.7% of patients, one year after insertion; hence the 
preinsertion haemoglobin, could not be compared with the post insertion haemoglobin, 
of the same patient. If this could have been done as a prospective study, a quantitative 
analysis could have been analysed and significance proved. 
h)  68.6% of patients had improved with Mirena symptomatically, and the mean duration 
was 5.3 months, in which improvement was noticed. The Amenorrhea rate was 47.8% 
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and almost 41.8% had regular but reduced bleeding. The commonest side effect was 
weight gain, followed by spotting. 
i) 76% of those who removed Mirena voluntarily, removed it in less than one year;  
Mean duration of removal of Mirena was 16.6 months ; around 54% of the removal 
was because, there was no improvement; and mean duration of expulsion was 6.5 
months;  only 6.3% of women who expelled had reinsertion of Mirena; while 45% of 
them who expelled had hysterectomy. 
j) The visual analogue score – The average pain before insertion was 86.6% which had 
reduced to 14.2% one year after insertion, with a 95% confidence interval of 66 to 78 
and p value was significant(<0.01). 
k) 68% of the patients were very much satisfied; and almost 83.5% of women were 
satisfied(very much satisfied and much satisfied);  
1) Comparing the UFS-QoL, before and after one year of Mirena, there was a 
significant improvement in the symptom severity, concern, activity, energy, 
control, self consciousness, sexual function, after one year of insertion of Mirena. 
The qualitative analysis done before insertion and one year after insertion of 
Mirena, in those with menorrhagia, by the UFS-QoL questionnaire,  showed that , 
the Symptom severity scoring by UFS-QoL, before and after insertion of Mirena , 
had an improvement, that was statistically significant. Similarly the  health related 
quality of life analysed by UFS-QoL , before and after one year after insertion 
also improved significantly, and was statistically significant. 
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l) The SF 36 scoring showed high scores proving that the quality of life was good, one 
year after insertion , but it could not be compared with SF before Mirena, for 
significance, as it was not done. The various aspects that are analysed are physical 
functioning, role of physical health, role of emotional problems, energy, emotional 
well being, social functioning and pain. 
m) There was no significant improvement in the  haemoglobin values before and after, 
because of the less numbers. 
n) Survival analysis- Overall duration of discontinuation of Mirena was 6 months ( 4 to 
7.9 months). The various reasons for removal were side effects, absence of 
improvement and hysterectomy, but the difference is not statiscally significant. 
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LIMITATIONS 
1) Anderson JK et al ,Br J Obstet Gynaecol 1990; 97: 690-4, states that the menstrual 
blood loss is reduced by 95% by 6 months and 97% at the end of 1 year. Therefore a 
sample size of 124 was chosen. However as this is an observational study on the 
patients who had Mirena in the past, the record of the contact number were not 
complete, and even if complete, were wrong numbers and wrong addresses. If done as 
a prospective analysis, it will be possible to have complete electronic records. 
2) All women did not have their haemoglobin checked, before and one year after 
insertion, and hence not comparable, causing inability to prove the significance. 
3) The questionnaires were elaborate causing inconvenience in postal interviews, though 
they were all translated in the regional language(hindi).  
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CONCLUSIONS 
1 The total number of patient who had insertion of  Mirena , from 2007 to 2011, in 
Christian Medical College and Hospital were 353. 
2 Though there was an improvement from mean preinsertion haemoglobin of 10.4 
gm% to post insertion haemoglobin of 11.5 gm%, this  improvement was not 
statistically significant . Hence the quantitative improvement could not be proved, 
statistically. 
3 The qualitative analysis done before insertion and one year after insertion of 
Mirena, in those with menorrhagia, by the UFS-QoL questionnaire,  showed that :  
a) The Symptom severity scoring by UFS-QoL, before and after insertion of 
Mirena , had an improvement, that was statistically significant. 
b) The  health related quality of life analysed by UFS-QoL , before and after one 
year after insertion also improved significantly, and was statistically 
significant. 
4 The effectiveness of Mirena in those with dysmenorrhea , before and after 
insertion of Mirena, analysed by the Visual analogue scale(VAS), showed that the 
mean change was 72.4%, and paired ‘t’ test, showed that the improvement was 
statistically significant. 
5 The health related quality of life, analysed by the SF 36, at one year after insertion 
of Mirena, showed that the mean score was ‘High’, which defines a more 
favourable health state. 
6 The level of satisfaction among those using Mirena, showed that 83.5% of 
patients were satisfied, out of which 68.2% of patients were very much satisfied. 
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7 Survival analysis showed that the median duration of Mirena removal was 6 
months.  If  the patients had waited, with additional medical therapy, removal 
could have been avoided, and they would have improved, at the end of one year. 
Around 23.4% of patients had expulsion of Mirena.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl no hospital no Age bmi Interview Reason symptom Cycles Bleeding daysDysmen pre Hb PostHb USG biopsy Med Rx improvement in months
1 59719 D 47 24.46 1 1 1 1 15 1 -  - 2 1 1 3
2 204445 B 39 23.78 2 1 1 1 8 2 8.3 11.8 2 2 - 3
3 690059 B 25.10 2 2 1 1 6 1 11.6  - 1 2 3 6
4 37376 D 45 29.97 1 4 1 1 8 1 10.7  - 1 1 2 12
5 691002 D 30 23.42 1 2 1 2 15 1 11.5  - 1 2 4 3
6 53676 B 36 22.19 1 1 1 2 7 1 11.0  - 1 2 2 12
7 917899 D 42 - 1 1 1 2 8 2 -  - 1 2 - 3
8 478014 D 46 - 1 1 1 1 5 2 10.6 12.1 1 2 3 6
9 351275 D 49 19.56 2 2 1 2 5 2 -  - 1 2 - 6
10 529767 B 43 - 2 4 1 1 5 2 8.4 13.2 1 2 1 3
11 939225 D 41 33.32 1 1 1 1 5 1 - 10.5 1 1 2 3
12 36330 D 38 - 3 1 1 2 7 1 -  - 2 1 3 6
13 743481 D 34 16.89 3 2 2 1 51 1 10.7  - 1 2 3 6
14 188576 A 49 24.88 2 1 1 1 10 1 12.4  - 1 2 3 3
15 624377 B 37 27.53 1 1 1 2 4 2 11.9  - 1 2 2 31
16 622947 D 25 17.78 1 1 1 1 8 1 6.2  - 2 1 - 6
17 989608 C 48 23.81 1 1 1 1 7 1 10.8 12.4 2 2 3 3
18 81515 F 35 26.91 1 1 1 1 6 1 -  - 2 2 3 3
19 841650 A 49 26.14 3 1 1 1 8 2 11.4 12.1 1 1 1 12
20 840762 D 47 32.04 2 1 1 1 5 2 13.2  - 1 1 1 6
21 620445 D 50 38.57 2 1 1 2 7 1 17.0  - 1 1 - 3
22 126233 C 32 22.83 2 1 1 1 8 1 8.9  - 1 2 1 3
23 914763 D 39 30.22 2 1 1 1 15 1 -  - 1 2 2 3
24 958998 D 36 19.65 3 3 1 1 12 1 - 13.0 1 2 3 6
25 729730 B 37 - 2 2 1 1 8 1 11.3  - 1 2 3 6
26 356806 D 32 22.31 2 2 1 2 8 2 -  - 1 2 2 6
27 770835 D 35 29.14 1 1 1 2 10 2 - - 1 2 3 3
28 833526 D 38 24.39 3 2 2 1 3 1 - - 1 2 3 6
29 446780 D 32 - 1 3 1 1 7 1 - - 1 2 - 6
30 536981 D 36 - 1 3 1 1 15 1 8.9 - 1 2 3 6
31 761374 D 47 28.13 1 1 1 2 15 1 - - 2 1 - 12
32 364833 A 43 30.80 2 1 1 1 5 2 - - 1 2 1 3
33 941364 C 32 18.31 1 1 1 1 7 2 12.1 - 1 2 - 6
Sl no hospital no Age bmi Interview Reason symptom Cycles Bleeding daysDysmen pre Hb PostHb USG biopsy Med Rx improvement in months
34 794175 C 32 19.23 1 1 1 1 8 1 - - 1 2 - 3
35 839468 D 42 27.66 1 4 1 1 8 1 11.7 - 1 1 1 -
36 944025 D 38 26.57 1 1 1 2 15 2 7.5 - 1 2 3 3
37 168468 A 44 27.24 1 1 1 1 10 2 - - 1 1 - 3
38 990035 B 38 25.15 1 4 1 1 6 1 10.9 - 1 1 3 3
39 623755 D 47 21.88 3 1 1 2 10 2 - - 2 2 3 6
40 954746 C 34 22.31 1 1 1 2 12 1 - - 1 2 3 6
41 397081 C 49 24.80 2 1 1 1 15 1 12.4 12.7 1 2 - 6
42 755945 D 26 27.77 2 2 2 2 3 1 - - 1 2 3 3
43 831195 D 44 24.44 1 1 1 1 3 2 13.5 - 1 2 1 12
44 995812 A 49 26.49 1 1 1 2 10 1 - 14.6 1 2 2 6
45 66769 F 38 22.03 1 1 1 1 9 1 - - 2 1 2 12
46 656769 D 40 21.64 1 1 1 1 5 1 - - 1 2 3 3
47 781086 D 39 22.22 1 1 1 1 6 1 - - 2 2 - 6
48 35603 F 40 32.84 1 1 2 1 7 1 - - 1 2 2 6
49 682807 D 40 27.11 1 2 1 1 4 1 - - 2 2 3 3
50 863514 D 48 22.21 3 3 1 2 3 2 - - 1 2 3 6
51 637566 D 38 26.48 1 2 2 1 5 1 12.2 - 2 2 1 3
52 587109 D 32 30.70 1 2 2 2 12 1 13.5 - 1 2 3 3
53 918735 D 41 34.89 1 1 1 1 5 2 - - 2 2 - 3
54 848602 D 42 26.67 3 1 1 1 10 2 10.8 - 2 2 - 12
55 459651 D 39 35.65 3 1 1 1 14 1 11.4 - 1 2 - 6
56 870993 D 39 32.47 1 1 1 1 6 2 - - 2 2 3 3
57 344728 D 33 21.23 1 2 2 1 5 1 - - 1 2 3 3
58 420430 D 36 20.83 1 1 1 1 8 2 11.9 - 1 2 - -
59 766602 D 31 26.49 1 2 2 1 5 1 - - 1 2 3 6
60 670768 D 35 31.47 1 3 2 1 3 1 - - 1 2 3 3
61 730937 B 35 24.14 1 2 1 1 4 1 - 13.0 1 1 1 3
62 135558 D 38 22.67 3 4 1 1 8 2 12.2 - 1 2 2 6
63 569784 D 39 23.44 3 2 1 1 6 1 - - 2 2 4 6
64 828652 D 32 26.22 3 3 1 1 15 2 - - 1 2 3 6
65 840001 D 42 25.78 3 1 1 1 4 2 10.8 - 1 2 3 6
66 769070 D 42 26.40 3 1 1 2 6 2 - - 1 2 3 6
Sl no hospital no Age bmi Interview Reason symptom Cycles Bleeding daysDysmen pre Hb PostHb USG biopsy Med Rx improvement in months
67 741907 D 42 30.63 1 1 1 1 12 1 12.8 - 1 1 3 -
68 934551 D 38 31.23 3 1 1 1 10 1 - - 2 2 - 6
69 954640 D 27 22.27 1 1 1 1 15 1 13.0 - 1 2 1 3
70 25495 D 49 24.78 1 1 1 2 10 1 9.8 - 1 1 2 6
71 8637 D 34 23.73 1 1 1 1 7 1 10.0 - 1 2 3 3
72 714136 B 32 28.67 1 1 1 2 10 1 13.3 13.1 2 1 - 3
73 796240 D 37 29.43 3 2 2 1 3 1 - - 1 2 1 6
74 665772 D 40 - 3 1 1 1 15 2 4.7 9.8 1 2 - 12
75 864519 D 30 34.16 1 3 1 1 3 1 - - 2 2 - 3
76 738965 D 34 23.05 1 2 2 2 8 1 - - 2 2 2 6
77 666521 D 47 34.25 1 3 1 1 5 1 9.2 10.6 1 2 2 6
78 487177 D 41 25.24 1 2 1 2 8 1 8.9 - 1 1 3 6
79 311794 D 36 32.87 1 1 1 1 8 1 13.3 - 1 2 2 6
80 732671 D 41 28.30 1 2 1 2 6 1 - - 1 2 3 12
81 81515 F 36 26.64 1 4 1 1 7 1 - - 2 2 3 3
82 35603 F 39 27.83 1 3 1 1 8 1 - - 1 2 3 6
83 988938 D 41 26.50 1 3 1 1 8 1 - - 1 2 3 3
84 211463 D 31 17.44 1 1 1 1 10 2 11.6 - 1 2 - 12
85 803930 C 34 27.63 1 2 1 1 5 1 11.3 11.6 1 2 - 3
86 31984 D 40 24.65 1 1 1 2 7 1 - - 2 2 3 3
87 44651 C 40 29.24 1 1 1 1 8 2 10.3 - 1 2 2 3
88 827952 D 31 27.27 1 2 2 2 - 2 - - 2 2 3 6
89 35154 F 32 - 1 3 2 1 3 1 10.8 - 1 2 - 6
90 404731 D 39 25.48 1 3 1 1 8 2 12.0 11.8 2 2 3 3
91 278563 F 40 25.48 1 1 1 1 6 2 7.7 11.5 1 2 - 3
92 338497 D 37 18.51 1 2 2 1 5 1 - - 1 2 - 3
93 963026 C 45 33.32 1 1 1 1 7 1 - - 1 1 1 6
94 84807 F 33 17.71 1 3 2 1 6 1 - 11.1 2 2 2 3
95 991637 d 46 23.31 1 2 2 2 6 1 - - 2 2 - 3
96 601598 D 38 23.92 1 3 2 1 5 1 11.5 - 1 1 3 6
97 519387 C 32 23.19 2 1 1 1 5 1 9.1 13.3 1 2 3 3
98 279512 D 39 34.58 1 1 1 1 5 1 11.4 - 2 2 - 6
99 390710 D 46 22.37 1 4 1 1 9 1 10.4 - 1 2 - 3
Sl no hospital no Age bmi Interview Reason symptom Cycles Bleeding daysDysmen pre Hb PostHb USG biopsy Med Rx improvement in months
100 838289 D 38 26.04 1 3 2 1 3 1 11.3 - 1 2 - 6
101 704818 D - 20.93 1 1 2 1 12 1 10.7 2.0 1 1 1 -
102 905924 D 34 21.93 1 2 2 1 3 1 - - 1 1 3 6
103 666853 D 29 22.84 3 3 1 1 4 2 12.1 - 1 2 3 6
104 79968 F 43 29.76 3 2 1 2 8 1 12.8 - 1 1 3 3
105 883027 D 32 22.60 3 4 1 1 8 2 - - 2 2 1 6
106 834520 D 49 - 2 1 1 2 6 1 4.7 9.0 1 1 1 3
107 335132 D 47 29.05 3 4 1 2 5 1 10.7 11.9 1 1 - 3
108 717535 D 25 18.13 1 1 1 1 7 2 11.8 - 1 2 3 12
109 928738 D 44 24.35 3 3 1 1 3 2 - - 2 2 - 6
110 787835 D 38 29.24 3 2 2 1 3 1 - - 1 2 3 6
111 793628 D 46 34.70 1 1 1 1 5 - - - - - - -
112 676339 D 46 30.02 1 4 1 2 12 2 13.1 - 1 1 1 -
113 110067 D 35 25.92 1 2 2 1 3 2 - - 1 2 3 -
114 266584 D 35 28.62 1 2 2 1 3 1 14.1 - 1 2 2 -
115 251235 D 46 27.41 1 1 1 2 13 1 12.0 - 2 2 - -
116 811545 D 40 22.94 1 1 1 1 8 2 8.4 - 2 2 - -
117 910350 D 34 16.44 1 2 1 1 5 1 - - 1 2 3 -
118 919054 D 37 35.20 1 4 1 1 10 2 - - 1 2 1 -
119 755860 D 40 - 2 1 1 1 14 2 12.2 - 1 1 3 -
120 772148 D 37 34.96 1 1 1 1 5 2 9.2 - 1 1 - -
121 264743 C 42 22.22 1 4 1 1 12 2 9.9 - 1 1 3 -
122 237741 D 40 24.03 1 1 1 1 5 1 11.2 - 2 2 2 -
123 853665 B 36 - 1 3 1 1 5 1 - - 2 2 2 -
124 815301 A 47 - 1 1 1 2 5 2 9.5 - 2 2 - -
125 319183 D 35 29.09 1 3 2 1 5 1 - - 2 2 3 -
126 878288 D 43 - 1 1 1 1 10 2 12.1 - 2 2 - -
127 902885 D 32 28.44 1 3 2 1 5 1 9.2 - 1 2 1 -
128 703711 D 38 27.89 1 1 1 2 5 2 10.3 - 1 2 - -
129 811545 D 42 27.56 1 1 1 1 8 1 5.8 - 1 2 1 -
130 494803 D 30 20.57 1 2 2 1 1 1 - 10.7 1 2 3 -
131 578239 D 44 26.84 1 3 1 2 8 2 6.8 - 1 1 1 -
132 745292 D 40 - 1 4 1 1 7 1 - - 2 1 - -
Sl no hospital no Age bmi Interview Reason symptom Cycles Bleeding daysDysmen pre Hb PostHb USG biopsy Med Rx improvement in months
133 517373 D 33 23.53 1 1 1 1 7 2 - - 1 2 2 -
134 580100 D 36 27.24 1 1 1 1 5 2 6.6 - 1 2 2 -
135 435357 D 49 33.23 1 1 1 2 12 2 7.9 - 1 1 2 -
136 525842 D 45 28.33 1 4 1 1 6 1 - - 1 1 2 12
137 474541 D 35 24.24 - 2 2 1 4 1 - - 1 2 - -
138 761694 D 39 27.48 - 2 2 1 3 1 - - 1 2 3 -
139 195006 D 44 30.67 1 1 1 1 8 2 - - 1 1 1 -
140 54760 C 33 24.52 - 2 2 1 1 2 - - 1 2 3 -
141 878073 D 34 19.22 1 3 1 1 10 1 - - 1 2 3 -
142 298151 D 31 18.66 1 3 1 1 7 1 - - 1 2 3 -
143 831728 D 28 23.62 1 1 1 1 15 1 7.1 - 1 2 3 -
144 367906 D 47 31.23 1 3 1 2 8 1 13.3 - 1 2 1 -
145 612586 D 48 18.92 - 1 1 1 12 2 3.7 - 1 2 - -
146 369873 D 30 14.04 1 3 1 1 8 1 - - 1 2 3 -
147 821141 C 36 26.22 1 2 1 1 5 1 - - 2 2 4 -
148 573910 D 33 24.69 1 2 2 2 8 1 7.8 - 1 2 3 -
149 629467 D 32 - 1 3 1 1 6 1 - - 1 2 - -
150 936802 D 40 - - 1 1 1 5 2 8.4 - 1 2 - -
151 66769 F 38 26.56 1 1 1 1 10 1 6.6 - 1 2 1 -
152 457991 C 35 28.62 1 4 1 1 5 1 14.1 - 1 2 2 -
153 703458 A 28 18.99 - 2 2 1 3 1 12.5 - 1 2 3 -
154 732813 D 46 25.54 1 4 1 1 4 1 - - 1 2 1 -
155 827669 C 48 - - 1 1 1 6 2 7.8 - 1 1 1 3
156 77218 C 38 26.11 - 2 2 1 3 1 - - 1 2 - -
157 954746 C 38 26.64 - 4 1 1 8 1 - - 2 2 3 6
158 227822 D 38 - - 3 2 1 3 2 - - 1 2 2 6
159 55750 F 39 25.48 - 4 1 1 15 1 13.6 - 1 2 - -
160 462875 D 33 24.34 - 2 1 1 8 2 - - 1 2 3 -
161 834900 D 39 23.56 - 1 1 1 5 2 12.0 - 1 2 1 -
162 885587 D 39 - 1 3 1 1 15 1 11.8 13.0 1 1 1 -
163 40936 C 37 - - 1 1 2 15 2 - - 1 2 1 6
164 689016 D 48 27.77 - 1 1 1 5 2 11.9 - 1 1 1 3
165 691904 C 45 28.57 1 1 1 1 8 2 8.8 - 1 1 1 3
Sl no hospital no Age bmi Interview Reason symptom Cycles Bleeding daysDysmen pre Hb PostHb USG biopsy Med Rx improvement in months
166 298344 D 38 24.78 1 1 1 1 15 1 10.3 - 2 2 3 -
167 374670 D 37 23.31 3 4 2 1 3 1 - - 1 2 3 -
168 846071 D 29 - 1 1 1 1 3 1 - - 2 2 3 6
169 256697 D 38 - - 4 1 2 5 2 10.7 - 1 1 1 6
170 977587 D 37 - 1 3 2 1 3 1 - - 2 2 3 -
171 947264 D 34 - - 4 1 1 15 2 - 10.7 1 2 3 12
172 784682 D 35 25.22 1 1 1 1 15 2 13.3 - 1 2 3 6
173 954157 D 42 - - 1 1 1 5 2 9.3 12.4 1 1 - -
174 834900 D 44 37.53 - 1 1 1 15 1 7.3 - 1 1 - -
175 690023 D 38 26.64 1 1 1 1 15 2 3.2 - 2 2 - -
176 527590 D 36 28.58 1 1 1 1 5 2 8.4 - 1 2 1 -
177 538985 D 37 - 1 1 1 1 5 2 8.5 - 1 2 - -
Sl no post insertn patternAdv ffect Removal Reason Rem monthsexpulsion expel.in monthsreinsertion what tx before one satisfacti inference SF phy.health
1 3 2 - 2 - - - 20 0 7 3 100.00 100.00
2 3 2 - - 2 - - - - - 5 2 90.00 100.00
3 3 2 - - 1 25 2 2 70 20 4 1 100.00 100.00
4 1 2 - - 2 - - - 80 10 7 3 45.00 100.00
5 1 2 - - 2 - - - 100 0 7 3 80.00 100.00
6 2 2 - - 2 - - - 100 0 7 3 80.00 100.00
7 - 2 - - 2 - - - - - 7 3 100.00 100.00
8 1 2 - - 1 24 2 1 - - 5 2 100.00 0.00
9 3 2 - - 2 - - - - - 7 3 80.00 50.00
10 2 1 3 14 2 - 2 2 60 40 5 2 70.00 0.00
11 - 2 - - 2 - - - 80 0 7 3 100.00 100.00
12 3 2 - - 2 - - - - - 6 3 45.00 75.00
13 1 2 - - 2 - - - 100 30 2 1 75.00 0.00
14 1 2 - - 2 - - - 80 20 - - 75.00 100.00
15 1 2 - - 2 - - - - - 7 3 100.00 100.00
16 3 2 - - 2 - - - 100 0 7 3 90.00 100.00
17 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
18 1 2 - - 2 - - - 90 20 7 3 100.00 100.00
19 - 2 - - 2 - - - - - - 3 - -
20 1 2 - - 2 - - - - - 7 3 100.00 100.00
21 3 2 - - 2 - - - 100 20 7 3 85.00 100.00
22 1 2 - - 2 - - - 50 0 7 3 100.00 100.00
23 1 2 - - 2 - - - 80 0 7 3 90.00 100.00
24 - 2 - - 2 - - - 100 25 6 3 100.00 75.00
25 1 1 3 12 2 - - - 100 50 5 2 95.00 100.00
26 - 1 3 40 2 - - - - - 5 2 80.00 50.00
27 - 2 - - 2 - - - - - 7 3 100.00 100.00
28 - 2 - - 2 - - - 70 30 6 3 50.00 100.00
29 - 2 - - 1 27 2 2 100 0 7 3 100.00 100.00
30 - 2 - - 2 - - - 100 0 7 3 100.00 100.00
31 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
32 3 2 - - 2 - - - - - 7 3 75.00 100.00
33 1 2 - - 2 - - - - - 7 3 100.00 100.00
Sl no post insertn patternAdv ffect Removal Reason Rem monthsexpulsion expel.in monthsreinsertion what tx before one satisfacti inference SF phy.health
34 3 2 - - 2 - - - 100 30 7 3 100.00 100.00
35 - 1 2 15 2 - - 2 90 60 5 2 65.00 25.00
36 1 2 - - 2 - - - - - 7 3 100.00 100.00
37 3 2 - - 2 - - - - - 6 3 100.00 100.00
38 2 2 - - 2 - - - 80 30 6 3 100.00 100.00
39 - 2 - - 2 - - - - - 5 2 90.00 0.00
40 2 2 - - 1 22 2 2 100 40 5 2 100.00 100.00
41 - 2 - - 2 - - - 20 0 7 3 100.00 100.00
42 3 2 - - 2 - - - 100 20 7 3 100.00 100.00
43 3 2 - - 2 - - - - - 6 3 70.00 100.00
44 3 2 - - 2 - - - 100 20 7 3 100.00 100.00
45 - 2 - - 2 - - - 100 10 7 3 100.00 100.00
46 3 2 - - 2 - - - 80 0 7 3 100.00 100.00
47 1 2 - - 2 - - - 100 10 7 3 100.00 100.00
48 1 2 - - 2 - - - 100 30 7 3 100.00 100.00
49 - 2 - - 2 - - - 100 0 7 3 100.00 100.00
50 2 2 - - 2 - - - - - 5 2 55.00 25.00
51 3 2 - - 2 - - - 100 10 6 3 100.00 100.00
52 3 2 - - 2 - - - 100 10 7 3 70.00 75.00
53 - 2 - - 2 - - - - - 7 3 100.00 100.00
54 2 2 - - 2 - - - - - 5 2 45.00 50.00
55 - 2 - - 2 - - - 100 20 6 3 80.00 100.00
56 1 2 - - 2 - - - - - 7 3 100.00 100.00
57 1 2 - - 2 - - - 80 0 7 3 100.00 100.00
58 - 2 - - 1 24 2 1 - - 2 1 65.00 0.00
59 - 2 - - 2 - - - 80 10 6 3 100.00 100.00
60 - 2 - - 2 - - - 100 10 7 3 100.00 100.00
61 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
62 3 2 - - 2 - - - - - - 3 - -
63 1 2 - - 2 - - - 90 0 6 3 55.00 25.00
64 1 2 - - 2 - - - - - 7 3 75.00 100.00
65 1 2 - - 2 - - - - - 7 3 85.00 25.00
66 - 2 - - 2 - - - - - 5 2 60.00 100.00
Sl no post insertn patternAdv ffect Removal Reason Rem monthsexpulsion expel.in monthsreinsertion what tx before one satisfacti inference SF phy.health
67 - 1 1 12 2 - 2 1 90 100 2 1 100.00 100.00
68 1 2 - - 2 - - - 60 0 7 3 50.00 25.00
69 1 2 - - 2 - - - 50 0 7 3 100.00 100.00
70 3 2 - - 2 - - - 75 0 7 3 100.00 100.00
71 1 2 - - 2 - - - 50 25 7 3 100.00 100.00
72 3 1 1 48 2 - 2 1 85 0 7 3 100.00 100.00
73 1 2 - - 2 - - - 60 0 7 3 90.00 75.00
74 1 2 - - 2 - - - - - 5 2 50.00 50.00
75 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
76 1 2 - - 2 - - - 100 10 7 3 100.00 100.00
77 3 2 - - 2 - - - 90 5 7 3 100.00 100.00
78 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
79 3 2 - - 2 - - - 100 10 7 3 85.00 100.00
80 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
81 2 2 - - 2 - - - 100 20 7 3 100.00 100.00
82 - 2 - - 2 - - - 100 30 7 3 100.00 100.00
83 - 2 - - 2 - - - 100 0 7 3 100.00 100.00
84 - 2 - - 2 - - - - - 7 3 100.00 100.00
85 - 2 - - 2 - - - 100 40 7 3 100.00 100.00
86 - 2 - - 2 - - - 50 0 6 3 100.00 100.00
87 1 2 - - 2 - - - - - 7 3 100.00 100.00
88 - 2 - - 2 - - - 100 10 7 3 100.00 100.00
89 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
90 - 2 - - 2 - - - 40 0 7 3 100.00 100.00
91 3 2 - - 2 - - - - - 7 3 100.00 100.00
92 - 2 - - 2 - - - 100 0 7 3 90.00 100.00
93 3 1 - 60 2 - 2 - 100 0 7 3 100.00 100.00
94 3 2 - - 2 - - - 100 0 7 3 100.00 100.00
95 - 2 - - 2 - - - 100 0 7 3 100.00 100.00
96 - 2 - - 2 - - - 100 0 7 3 85.00 100.00
97 - 2 - - 2 - - - 90 10 6 3 100.00 100.00
98 1 2 - - 2 - - - 80 30 7 3 100.00 100.00
99 - 2 - - 2 - - - 90 0 7 3 100.00 100.00
Sl no post insertn patternAdv ffect Removal Reason Rem monthsexpulsion expel.in monthsreinsertion what tx before one satisfacti inference SF phy.health
100 - 2 - - 2 - - - 100 20 6 3 100.00 100.00
101 - 2 - - 2 - - - 60 90 1 1 50.00 25.00
102 - 2 - - 2 - - - 90 40 6 3 100.00 100.00
103 - 2 - - 2 - - - - - 2 1 25.00 50.00
104 - 2 - - 2 - - - 100 50 6 3 70.00 100.00
105 - 2 - - 2 - - - - - 7 3 75.00 75.00
106 - 2 - - 2 - - - 30 0 6 3 100.00 100.00
107 - 2 - - 2 - - - 100 0 7 3 40.00 25.00
108 - 2 - - 2 - - - - - 7 3 90.00 100.00
109 3 2 - - 2 - - - - - 7 3 70.00 100.00
110 - 2 - - 2 - - - 80 30 7 3 75.00 50.00
111 - - - - - - - - - - - - - -
112 - 2 - - 1 1 2 2 - - - - - -
113 - 2 - - 1 2 2 1 - - - - - -
114 - 2 - - 1 3 2 1 - - - - - -
115 - 1 1 10 2 - 2 2 - - - - - -
116 - 2 - - 1 10 2 2 - - - - - -
117 - 2 - - 1 1 2 1 - - - - - -
118 - 1 2 9 2 - 2 2 - - - - - -
119 - 2 - - 1 1 2 1 - - - - - -
120 - 2 - - 1 3 2 1 - - - - - -
121 - 3 - - 2 1 2 1 - - - - - -
122 - 1 2 5 2 - 2 1 - - - - - -
123 - 2 - - 1 3 2 2 - - - - - -
124 - 2 - - 1 1 2 2 - - - - - -
125 - 1 2 4 2 - 2 2 - - - - - -
126 - 1 2 10 2 - 2 2 - - - - - -
127 - 2 - - 1 3 2 1 - - - - - -
128 - 2 - - 1 6 2 1 - - - - - -
129 - 1 2 3 2 - 2 2 - - - - - -
130 - 1 2 15 2 - 2 2 - - - - - -
131 - 1 3 2 2 - 2 2 - - - - - -
132 - 1 2 9 2 - 2 2 - - - - - -
Sl no post insertn patternAdv ffect Removal Reason Rem monthsexpulsion expel.in monthsreinsertion what tx before one satisfacti inference SF phy.health
133 - 2 - - 1 3 2 1 - - - - - -
134 - 2 - - 1 5 2 1 - - - - - -
135 - 2 - - 1 3 2 1 - - - - - -
136 - 2 - - 2 - - - - - - - - -
137 - 1 1 12 2 - 1 - - - - - - -
138 - 1 2 6 2 - 2 1 - - - - - -
139 - 2 - - 1 11 2 1 - - - - - -
140 - 1 2 3 2 - 2 2 - - - - - -
141 - 2 - - 1 2 2 1 - - - - - -
142 - 2 - - 1 2 2 2 - - - - - -
143 - 2 - - 1 3 2 1 - - - - - -
144 - 2 - - 1 3 2 2 - - - - - -
145 - 2 - - 1 12 2 1 - - - - - -
146 - 2 - - 1 2 1 - - - - - - -
147 - 1 2 8 2 - 2 2 - - - - - -
148 - 2 - - 1 4 2 1 - - - - - -
149 - 2 - - 1 6 2 2 - - - - - -
150 - 2 - - 1 6 2 1 - - - - - -
151 - 2 - - 1 6 2 1 - - - - - -
152 - 2 - - 1 6 2 1 - - - - - -
153 - 2 - - 1 12 2 1 - - - - - -
154 - 2 - - 1 2 2 1 - - - - - -
155 - 2 - - 1 9 2 1 - - - - - -
156 - 2 - - 2 - - - - - - - - -
157 - 1 3 12 2 - 2 2 - - - - - -
158 - 1 3 36 2 - - 2 - - - - - -
159 - 2 - - 1 4 2 1 - - - - - -
160 - 1 2 24 2 - 2 2 - - - - - -
161 - 2 - - 1 1 2 1 - - - - - -
162 - 2 - - 1 1 2 2 - - - - - -
163 - 2 - - 2 - - - - - - - - -
164 - 2 - - 2 - - - - - - - - -
165 - 2 - - 2 - - - - - - - - -
Sl no post insertn patternAdv ffect Removal Reason Rem monthsexpulsion expel.in monthsreinsertion what tx before one satisfacti inference SF phy.health
166 - 2 - - 1 1 1 - - - - - - -
167 - 2 - - 1 1 1 - - - - - - -
168 - 2 - - 2 - - - - - - - - -
169 - 2 - - 2 - - - - - - - - -
170 - 1 2 24 2 - 2 1 - - - - - -
171 - 2 - - 2 - - - - - - - - -
172 - 1 1 24 2 - 2 2 - - - - - -
173 - 2 - - 1 11 2 1 - - - - - -
174 - 2 - - 1 2 2 1 - - - - - -
175 - 2 - - 2 - - - - - - - - -
176 - - - - - - - - - - - - - -
177 - 2 - - 2 - - - - - - - - -
Sl no SF Phy,h Role emotionalEnergy Emotional Social Pain Genhealth UFS btotal UFSatotal .UFS sym.bUFS sym a HRQLTotal_b
1 100.00 85.00 92.00 100.00 100.00 90.00 121.00 36.00 22.00 9.00 99.00 27.00
2 0.00 40.00 48.00 25.00 100.00 70.00 111.00 46.00 18.00 8.00 93.00 38.00
3 100.00 65.00 88.00 100.00 90.00 90.00 76.00 53.00 15.00 15.00 61.00 38.00
4 100.00 75.00 80.00 100.00 100.00 55.00 123.00 39.00 22.00 9.00 101.00 30.00
5 100.00 85.00 100.00 100.00 100.00 95.00 156.00 40.00 27.00 11.00 129.00 29.00
6 100.00 75.00 84.00 100.00 90.00 95.00 103.00 37.00 21.00 8.00 zz 29.00
7 100.00 90.00 96.00 100.00 90.00 95.00 138.00 44.00 24.00 9.00 114.00 35.00
8 0.00 40.00 44.00 87.50 100.00 35.00 126.00 117.00 26.00 17.00 100.00 100.00
9 33.33 70.00 92.00 87.50 67.50 70.00 105.00 55.00 23.00 13.00 82.00 42.00
10 0.00 55.00 64.00 62.50 45.00 25.00 123.00 73.00 28.00 12.00 95.00 61.00
11 100.00 95.00 92.00 100.00 100.00 95.00 139.00 41.00 27.00 8.00 112.00 33.00
12 100.00 65.00 64.00 50.00 80.00 40.00 142.00 91.00 36.00 30.00 106.00 61.00
13 0.00 30.00 40.00 50.00 0.00 10.00 124.00 111.00 25.00 22.00 99.00 89.00
14 100.00 75.00 80.00 75.00 100.00 65.00 94.00 99.00 27.00 20.00 67.00 79.00
15 100.00 90.00 92.00 100.00 100.00 80.00 149.00 49.00 27.00 11.00 122.00 38.00
16 33.33 75.00 100.00 87.50 100.00 90.00 141.00 39.00 23.00 8.00 118.00 31.00
17 100.00 80.00 80.00 100.00 100.00 90.00 113.00 38.00 23.00 8.00 90.00 30.00
18 100.00 80.00 84.00 100.00 90.00 95.00 130.00 41.00 23.00 8.00 107.00 33.00
19 - - - - - - - - - - - -
20 100.00 80.00 68.00 87.50 100.00 85.00 118.00 38.00 22.00 8.00 96.00 30.00
21 100.00 85.00 88.00 100.00 100.00 90.00 148.00 47.00 26.00 8.00 122.00 39.00
22 100.00 95.00 96.00 100.00 100.00 100.00 148.00 40.00 27.00 8.00 121.00 32.00
23 100.00 80.00 80.00 100.00 90.00 90.00 139.00 39.00 24.00 8.00 115.00 31.00
24 100.00 65.00 64.00 50.00 32.50 55.00 128.00 51.00 37.00 12.00 91.00 39.00
25 100.00 70.00 92.00 62.50 45.00 50.00 112.00 43.00 25.00 11.00 87.00 32.00
26 100.00 45.00 68.00 75.00 67.50 45.00 121.00 103.00 27.00 23.00 94.00 80.00
27 100.00 80.00 76.00 100.00 100.00 90.00 128.00 44.00 24.00 8.00 104.00 36.00
28 100.00 55.00 52.00 62.50 32.50 70.00 - - - - - -
29 100.00 90.00 92.00 100.00 100.00 100.00 139.00 37.00 28.00 8.00 111.00 29.00
30 100.00 95.00 100.00 100.00 100.00 100.00 158.00 40.00 35.00 8.00 123.00 32.00
31 100.00 85.00 84.00 100.00 100.00 95.00 129.00 37.00 26.00 8.00 103.00 29.00
32 100.00 60.00 60.00 75.00 77.50 70.00 111.00 60.00 22.00 9.00 89.00 51.00
33 100.00 90.00 84.00 100.00 100.00 100.00 132.00 39.00 19.00 8.00 113.00 31.00
Sl no SF Phy,h Role emotionalEnergy Emotional Social Pain Genhealth UFS btotal UFSatotal .UFS sym.bUFS sym a HRQLTotal_b
34 100.00 90.00 88.00 100.00 100.00 85.00 129.00 38.00 24.00 9.00 105.00 29.00
35 33.33 70.00 80.00 62.50 90.00 40.00 127.00 128.00 21.00 21.00 106.00 107.00
36 100.00 85.00 80.00 100.00 100.00 85.00 124.00 39.00 24.00 8.00 100.00 31.00
37 100.00 80.00 88.00 100.00 90.00 100.00 76.00 43.00 19.00 8.00 57.00 35.00
38 100.00 80.00 72.00 100.00 100.00 85.00 133.00 42.00 20.00 10.00 113.00 32.00
39 0.00 25.00 4.00 50.00 0.00 45.00 104.00 83.00 29.00 18.00 75.00 65.00
40 100.00 85.00 84.00 100.00 90.00 95.00 135.00 89.00 25.00 16.00 110.00 73.00
41 100.00 90.00 88.00 100.00 100.00 95.00 148.00 40.00 29.00 8.00 119.00 32.00
42 100.00 90.00 88.00 100.00 100.00 75.00 156.00 41.00 30.00 10.00 126.00 31.00
43 100.00 75.00 76.00 100.00 77.50 75.00 128.00 41.00 22.00 8.00 106.00 33.00
44 100.00 80.00 84.00 100.00 90.00 85.00 137.00 43.00 24.00 9.00 113.00 34.00
45 100.00 75.00 80.00 100.00 100.00 80.00 122.00 47.00 21.00 9.00 101.00 38.00
46 100.00 65.00 76.00 100.00 100.00 85.00 112.00 39.00 22.00 8.00 90.00 31.00
47 100.00 80.00 84.00 100.00 100.00 95.00 118.00 45.00 19.00 11.00 99.00 34.00
48 100.00 75.00 84.00 100.00 100.00 90.00 115.00 42.00 20.00 8.00 95.00 34.00
49 100.00 90.00 76.00 100.00 100.00 90.00 145.00 38.00 26.00 8.00 119.00 30.00
50 66.67 80.00 60.00 75.00 45.00 35.00 71.00 44.00 16.00 9.00 55.00 35.00
51 100.00 80.00 80.00 100.00 100.00 90.00 127.00 42.00 22.00 8.00 105.00 34.00
52 100.00 40.00 64.00 62.50 75.00 55.00 124.00 90.00 33.00 23.00 91.00 67.00
53 100.00 85.00 84.00 100.00 100.00 95.00 133.00 44.00 23.00 8.00 110.00 36.00
54 33.33 15.00 28.00 100.00 35.00 45.00 103.00 86.00 22.00 17.00 81.00 69.00
55 100.00 100.00 80.00 87.50 90.00 95.00 162.00 62.00 29.00 11.00 133.00 51.00
56 100.00 90.00 84.00 100.00 90.00 95.00 142.00 49.00 25.00 12.00 117.00 37.00
57 100.00 90.00 92.00 100.00 100.00 100.00 - - - - - -
58 0.00 40.00 48.00 25.00 100.00 35.00 142.00 160.00 27.00 30.00 115.00 130.00
59 100.00 60.00 72.00 100.00 77.50 70.00 120.00 72.00 23.00 16.00 97.00 56.00
60 100.00 90.00 92.00 100.00 100.00 90.00 - - - - - -
61 100.00 80.00 84.00 100.00 77.50 85.00 130.00 40.00 23.00 8.00 107.00 32.00
62 - - - - - - 64.00 - 25.00 - 39.00 -
63 66.67 35.00 28.00 87.50 45.00 20.00 144.00 87.00 27.00 16.00 117.00 71.00
64 66.67 95.00 92.00 87.50 90.00 90.00 141.00 84.00 24.00 24.00 117.00 60.00
65 33.33 95.00 92.00 50.00 10.00 65.00 131.00 44.00 31.00 11.00 100.00 33.00
66 100.00 60.00 52.00 87.50 55.00 100.00 73.00 61.00 18.00 16.00 55.00 45.00
Sl no SF Phy,h Role emotionalEnergy Emotional Social Pain Genhealth UFS btotal UFSatotal .UFS sym.bUFS sym a HRQLTotal_b
67 100.00 85.00 76.00 100.00 100.00 85.00 145.00 44.00 24.00 9.00 121.00 35.00
68 66.67 60.00 56.00 87.50 45.00 35.00 123.00 75.00 26.00 17.00 97.00 58.00
69 100.00 85.00 80.00 100.00 100.00 80.00 152.00 37.00 27.00 8.00 125.00 29.00
70 100.00 90.00 92.00 100.00 100.00 90.00 123.00 46.00 25.00 9.00 98.00 37.00
71 100.00 90.00 88.00 100.00 100.00 90.00 129.00 42.00 23.00 11.00 106.00 31.00
72 100.00 80.00 76.00 100.00 100.00 90.00 118.00 40.00 25.00 8.00 93.00 32.00
73 100.00 60.00 96.00 100.00 42.50 100.00 - - - - - -
74 33.33 20.00 32.00 37.50 47.50 30.00 148.00 74.00 32.00 16.00 116.00 58.00
75 100.00 90.00 92.00 100.00 100.00 100.00 117.00 37.00 21.00 8.00 96.00 29.00
76 100.00 90.00 92.00 100.00 100.00 95.00 142.00 39.00 32.00 8.00 110.00 31.00
77 100.00 55.00 88.00 100.00 90.00 90.00 143.00 44.00 24.00 8.00 119.00 36.00
78 100.00 80.00 84.00 87.50 90.00 95.00 126.00 39.00 25.00 8.00 101.00 31.00
79 100.00 65.00 84.00 100.00 90.00 85.00 135.00 38.00 26.00 8.00 109.00 30.00
80 100.00 85.00 80.00 100.00 100.00 95.00 125.00 39.00 23.00 8.00 102.00 31.00
81 100.00 90.00 84.00 100.00 100.00 95.00 134.00 37.00 23.00 8.00 111.00 29.00
82 100.00 85.00 84.00 100.00 100.00 75.00 131.00 40.00 26.00 8.00 105.00 32.00
83 100.00 95.00 92.00 100.00 100.00 100.00 144.00 37.00 31.00 8.00 113.00 29.00
84 100.00 90.00 92.00 100.00 100.00 100.00 161.00 38.00 32.00 8.00 129.00 30.00
85 100.00 90.00 92.00 100.00 100.00 95.00 134.00 37.00 32.00 8.00 102.00 29.00
86 100.00 95.00 92.00 100.00 90.00 95.00 123.00 41.00 32.00 8.00 91.00 33.00
87 100.00 85.00 88.00 100.00 90.00 95.00 147.00 39.00 23.00 8.00 124.00 31.00
88 100.00 75.00 84.00 100.00 77.50 90.00 - - - - - -
89 100.00 90.00 92.00 100.00 100.00 100.00 159.00 42.00 31.00 9.00 128.00 33.00
90 100.00 80.00 76.00 100.00 90.00 75.00 129.00 47.00 23.00 12.00 106.00 35.00
91 100.00 80.00 84.00 100.00 100.00 95.00 124.00 42.00 20.00 8.00 104.00 34.00
92 100.00 80.00 84.00 100.00 90.00 90.00 - - - - - -
93 100.00 85.00 84.00 100.00 90.00 95.00 138.00 40.00 28.00 8.00 110.00 32.00
94 100.00 80.00 84.00 100.00 100.00 100.00 143.00 41.00 25.00 8.00 118.00 33.00
95 100.00 85.00 92.00 100.00 100.00 95.00 132.00 38.00 30.00 8.00 102.00 30.00
96 100.00 60.00 80.00 100.00 90.00 75.00 138.00 42.00 25.00 8.00 113.00 34.00
97 100.00 90.00 96.00 100.00 77.50 95.00 92.00 39.00 17.00 10.00 75.00 29.00
98 100.00 90.00 92.00 100.00 100.00 90.00 138.00 44.00 32.00 12.00 106.00 32.00
99 100.00 90.00 84.00 100.00 100.00 90.00 134.00 40.00 24.00 8.00 110.00 32.00
Sl no SF Phy,h Role emotionalEnergy Emotional Social Pain Genhealth UFS btotal UFSatotal .UFS sym.bUFS sym a HRQLTotal_b
100 100.00 80.00 72.00 100.00 90.00 70.00 - - - - - -
101 0.00 20.00 36.00 0.00 12.50 25.00 159.00 149.00 38.00 38.00 121.00 111.00
102 100.00 70.00 88.00 100.00 90.00 60.00 - - - - - -
103 66.67 40.00 20.00 87.50 22.50 20.00 145.00 115.00 28.00 17.00 117.00 98.00
104 0.00 10.00 36.00 12.50 45.00 40.00 133.00 88.00 25.00 15.00 108.00 73.00
105 100.00 80.00 76.00 100.00 90.00 95.00 113.00 82.00 34.00 21.00 79.00 61.00
106 100.00 85.00 88.00 100.00 100.00 90.00 143.00 40.00 29.00 8.00 114.00 32.00
107 100.00 70.00 72.00 50.00 45.00 40.00 156.00 48.00 30.00 17.00 126.00 31.00
108 100.00 75.00 96.00 100.00 90.00 70.00 159.00 39.00 30.00 9.00 129.00 30.00
109 100.00 15.00 16.00 50.00 22.50 40.00 119.00 80.00 25.00 12.00 94.00 68.00
110 33.33 80.00 64.00 87.50 100.00 85.00 92.00 74.00 20.00 15.00 72.00 59.00
111 - - - - - - - - - - - -
112 - - - - - - - - - - - -
113 - - - - - - - - - - - -
114 - - - - - - - - - - - -
115 - - - - - - - - - - - -
116 - - - - - - - - - - - -
117 - - - - - - - - - - - -
118 - - - - - - - - - - - -
119 - - - - - - - - - - - -
120 - - - - - - - - - - - -
121 - - - - - - - - - - - -
122 - - - - - - - - - - - -
123 - - - - - - - - - - - -
124 - - - - - - - - - - - -
125 - - - - - - - - - - - -
126 - - - - - - - - - - - -
127 - - - - - - - - - - - -
128 - - - - - - - - - - - -
129 - - - - - - - - - - - -
130 - - - - - - - - - - - -
131 - - - - - - - - - - - -
132 - - - - - - - - - - - -
Sl no SF Phy,h Role emotionalEnergy Emotional Social Pain Genhealth UFS btotal UFSatotal .UFS sym.bUFS sym a HRQLTotal_b
133 - - - - - - - - - - - -
134 - - - - - - - - - - - -
135 - - - - - - - - - - - -
136 - - - - - - - - - - - -
137 - - - - - - - - - - - -
138 - - - - - - - - - - - -
139 - - - - - - - - - - - -
140 - - - - - - - - - - - -
141 - - - - - - - - - - - -
142 - - - - - - - - - - - -
143 - - - - - - - - - - - -
144 - - - - - - - - - - - -
145 - - - - - - - - - - - -
146 - - - - - - - - - - - -
147 - - - - - - - - - - - -
148 - - - - - - - - - - - -
149 - - - - - - - - - - - -
150 - - - - - - - - - - - -
151 - - - - - - - - - - - -
152 - - - - - - - - - - - -
153 - - - - - - - - - - - -
154 - - - - - - - - - - - -
155 - - - - - - - - - - - -
156 - - - - - - - - - - - -
157 - - - - - - - - - - - -
158 - - - - - - - - - - - -
159 - - - - - - - - - - - -
160 - - - - - - - - - - - -
161 - - - - - - - - - - - -
162 - - - - - - - - - - - -
163 - - - - - - - - - - - -
164 - - - - - - - - - - - -
165 - - - - - - - - - - - -
Sl no SF Phy,h Role emotionalEnergy Emotional Social Pain Genhealth UFS btotal UFSatotal .UFS sym.bUFS sym a HRQLTotal_b
166 - - - - - - - - - - - -
167 - - - - - - - - - - - -
168 - - - - - - - - - - - -
169 - - - - - - - - - - - -
170 - - - - - - - - - - - -
171 - - - - - - - - - - - -
172 - - - - - - - - - - - -
173 - - - - - - - - - - - -
174 - - - - - - - - - - - -
175 - - - - - - - - - - - -
176 - - - - - - - - - - - -
177 - - - - - - - - - - - -
HRQLTotal_b
HRQLTotal_b
HRQLTotal_b
HRQLTotal_b
HRQLTotal_b
HRQLTotal_b
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                                   ABBREVIATIONS 
 
                    AUB – Abnormal uterine bleeding 
DNA – Deoxy ribonucleic acid 
DUB – Dysfunctional uterine bleeding 
FIGO – Fédération Internationale de Gynécologie et d'Obstétrique 
               (International     Federation of Obstetrics and Gynaecology) 
GnRh – Gonadotrophin releasing hormone 
HMB – Heavy menstrual bleeding 
LNG-IUS – Levonorgesterel intrauterine system 
NSAIDs- Non steroidal anti inflammatory drug 
OCP- Oral contraceptive pill 
PBAC- Pictorial blood loss assessment chart 
PG – Prostaglandin 
RBC – Red blood cell 
SLE – Systemic Lupus erythematoses 
TCRE – Transcervical resection of the endometrium 
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ANNEXURES 
ANNEXURE I 
INFORMED CONSENT 
 
Christian Medical College, Vellore 
Department of obstetrics & Gynecology 
 
 Participant Information sheet 
 
Study on follow up of patients on MIRENA inserted at CMC VELLORE,  
You are being requested to participate in a study to see  the effectiveness of 
inserting MIRENA in the medical management of excessive bleeding during menstrual 
cycles and to study the improvement in the Health Related Quality of Life. We hope to 
include about 300 people in this study. 
 
What is the need for the study ? 
Heavy menstrual bleeding is a common problem in women of reproductive age. 
It is expensive to treat and can severely affect the woman’s quality of life. Many women 
are not happy with the medical treatment and prefer surgery. MIRENA  is the non 
surgical alternative , which is reversible and spares childbearing. Studies have proved 
that MIRENA is safe and equally effective for all age group of women, improving the 
quality of life. Even in our hospital many women benefit from the insertion of MIRENA, 
which is yet to be studied. If you are part of this study, and if the beneficial effects are 
proven, it will benefit many other women, and help them to decide not to have 
hysterectomy( removal of uterus) 
 
Is there a harm to you in participating in the study? 
There will be no harm to you during participation in the study.  The standard 
routine care will continue independent of the study result. 
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If you take part what will you have to do? 
If you agree to participate in this study, you will be mailed a set of questionnaire 
which has to be answered, in relation to your bleeding pattern during menstrual cycle, 
the associated symptoms, the health problems faced,  before insertion of MIRENA and 
then to follow up with the improvement of symptoms, and the quality of life after 
insertion of MIRENA.  No additional procedures will be conducted for this study.  
 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to 
decide to withdraw permission to participate in this study. If you do so, this will not 
affect your usual treatment at this hospital in any way.  
 
Will you have to pay for the study ?  
NO payment required for the study. The postal charges will be paid by us. Any 
other treatment that you usually take will continue and the routine charges for the 
treatment will be paid by you.  
 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without your additional 
permission, should you decide to participate in this study.  
 
If you have any further questions, please ask Dr.Latha Lakshmi, Dr.Alice George(tel: 
9994629053 or email to og1@cmcvellore.ac.in 
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CONSENT TO TAKE PART IN A CLINICAL TRIAL 
Study Title: Study of Follow up of Patients on MIRENA INSERTION 
 
Study Number:  
Participant’s name:  
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
 
___________, wife of  ___________________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provided to me regarding this 
study and have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that 
I am free to withdraw permission to continue to participate at any time without 
affecting my usual treatment or my legal rights [ ] 
I also understand that neither I, nor my doctors, will have any  knowledge of  the  
result during the study[ ]  
I understand that I will not be charged anything under the study[ ] 
I understand that the study staff and institutional ethics committee members 
will not need my permission to look at my health records even if I withdraw from the 
trial. I agree to this access   [ ]   
I understand that my identity will not be revealed in any information released to 
third parties or published [ ]   
I voluntarily agree to take part in this study [ ] 
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Name: 
Signature: 
Date: 
 
Name of witness: 
Relation to participant: 
Date: 
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Annexure II 
 
GENERAL PROFORMA 
GP 1)Name :-                                                                                2) Hospital No -                      
      3)Husband’s name:-                                                                4)  I.D No          - 
      5) Patient’s age / Date of Birth-                                              6) Telephone No-                  
     7)Reason for insertion                                                              8) e mail id-                                                                  
     9)Date of insertion 
GP  10)Indication for MIRENA:-1) Menorrhagia (    ) 
                                                      2) Dysmenorrhea (   ) 
                                                      3) Dyspareunia (   ) 
                                                      4) Contraception(  ) 
                                                      5) Endometrial Hyperplasia(   ) 
11)  Parity- a)P (  ) b) L  (  ) 
12) Menstrual History a) Prior menstrual periods :- Regular(1) /Irregular(2) 
b) EXCESSIVE FLOW: Yes(1)/ No(2) 
c) No of days – 1) < 3 days 2) 3 – 5 days 3) 5- 8 days 4) > 8 days  
13) Dysmenorrhea – Yes(1)/  No(2) 
14) Pre insertion Hb (    ) gm%   
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15) 
1 
16)U/S Report - 
17)Endometrial biopsy done      - Yes(1)   /    No (2) 
18)Bx Report – 
GP 19) In addition to Mirena 
     1)Used Progesterones – Yes(1)  / No(2) 
     2)Used NSAIDs/ Tranexemic acid –Yes (1)  / No ( 2) 
     3) Used OCPs – Yes (1)/ No (2) 
     4) Used Danazol/ GnRh – Yes (1)  /No(2) 
20 ) Post insertion Hb – Yes (1)  / No (2) 
21) If Yes Hb -        gm% 
22) Bleeding symptoms – 1)Improved after 3 cycles  
                                       2) Improved after 6 cycles  
                                        3) Improved after 1 year 
 
 
 
 YES(1) NO(2) 
a-Treatment 
of anemia 
  
b-Iron 
supplements 
  
c- Thyroid 
disorder 
  
d-Ultrasound 
screening done 
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GP 23) SURVIVAL ANALYSIS 
1)   Voluntary Removal of Mirena - Yes (1) / No(2) 
2)   If Yes – Reason for removal 
3) If Yes – After how many years 
4) Spontaneous EXPULSION – Yes (1)  / No (2) 
5) If Yes – After how many years 
6) If Yes – Was it Reinserted – Yes (1) /No(2) 
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ANNEXURE III 
 
 
 
104 
 
 
 
 
105 
 
 
 
 
 
106 
 
ANNEXURE IV 
 
SF 36 
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ANNEXURE V 
 
 
PATIENT NAME 
ID NUMBER 
HOSPITAL NUMBER 
 
PLEASE INDICATE YOUR SUBJECTIVE LEVEL OF ENDOMETRIOSIS PAIN 
A) BEFORE INSERTION 
VISUAL ANALOG SCALE(VAS) 
 
0-------------------------------------------------------------100 
ABSENCE                                                                    UNBEARABLE  
OF  PAIN                                                                             PAIN 
0--- 10---20---30---40---50---60---70---80---90---100 
B) AFTER INSERTION 
 
VISUAL ANALOG SCALE(VAS) 
 
0-------------------------------------------------------------100 
ABSENCE                                                                    UNBEARABLE  
OF  PAIN                                                                             PAIN 
0--- 10---20---30---40---50---60---70---80---90---100 
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ANNEXURE  VI 
CLINICAL GLOBAL IMPRESSIONS SCALE 
PATIENT NAME 
ID NUMBER 
HOSPITAL NUMBER 
CLINICAL GLOBAL IMPRESSIONS SCALE (CGI SCALE – GLOBAL IMPROVEMENT  ITEM) 
7 --- VERY MUCH SATISFIED 
6 --- MUCH SATISFIED 
5 --- MINIMALLY SATISFIED 
4 --- NEITHER SATISFIED NOR DISSATISFIED 
3 --- MINIMALLY DISSATISFIED 
2 --- MUCH DISSATISFIED 
1 --- VERY MUCH DISSATISFIED 
 
 
 
INFERENCE 
6 & 7  ----- SATISFIED 
5        ------ MINIMALLY SATISFIED 
1 – 4 ------ UNDECIDED OR WORSE 
 
